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Abstract 
Positive sense RNA viruses include diverse groups of viruses that cause a wide variety of 
diseases in humans and animals. Most of these viruses encode proteases that cleave the viral 
polyprotein into intermediate or mature functional proteins during virus replication. As these 
proteases play a critical role in virus replication, they represent an attractive target for the 
development of antiviral drugs. In this study, the main goal was to establish assay systems 
and characterize the enzymatic activity of related proteases from Norwalk virus (NV), 
poliovirus, and transmissible gastroenteritis virus (TGEV). These proteases share several 
common characteristics including a typical chymotrypsin-like fold, a Cys residue as a 
nucleophile in the catalytic triad (or dyad) composed of Cys, His and Glu (or Asp) residues, 
and a preference for a Glu or Gln residue at the P1 position on the substrate. We cloned and 
expressed proteases from these viruses and characterized their enzymatic activities using a 
fluorescence resonance energy transfer (FRET) assay using a specific FRET substrate 
corresponding to each viral protease. First, assay conditions of the FRET assay was 
optimized for each virus protease. Second, inhibition profiles of each virus protein were 
investigated using five commercially available standard protease inhibitors (chymostatin, 
leupeptin, antipain, TPCK, and TLCK). The inhibition studies showed that TPCK inhibited 
NV, poliovirus, and TGEV proteases with varying strength, and chymostatin inhibited only 
NV protease. All other inhibitors had little effects on the virus proteases. The established 
FRET assays should facilitate screening potential antivirals.
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CHAPTER 1- PROTEASES LITERATURE REVIEW 
Introduction: 
           A large number of biochemical reactions that occur in life are almost mediated by a 
remarkable array of biological catalysts known as enzymes. Biochemical reactions that are 
catalyzed by the enzymes are involved in all facets of cellular life: metabolism (the chemical 
processes that occur within a living organism in order to maintain life by producing cellular 
building blocks and energy from food sources); biosynthesis (the production of complex 
molecules within living organisms or cells); detoxification (the process of removing toxic 
substances or qualities from cells); and information storage (the process of deoxyribonucleic 
acid synthesis (18) . Proteases also termed as peptidases or proteinases are enzymes which 
are widely distributed in cells. They catalyse the hydrolysis of peptide bonds that link amino 
acids together in the polypeptide chain forming the protein. This process is called proteolysis 
(Figure 1.1). Proteases are present in plant and animal tissues and also in microorganisms. 
About 2% of the human genome consists of proteases, whereas in case of infectious 
organisms and other form of life, they account for about 1-5% of the genomes (43), (1). 
Proteases form one of the extensive and most important groups of enzymes and involved in 
many important physiological processes occuring in living organisms like protein turnover, 
digestion, blood coagulation and wound healing, fertilization, cell differentiation and growth, 
cell signalling, immune response and apoptosis (96).  
           Proteases are found in different forms either soluble or associated with plasma 
membranes and subcellular organelles, or even secreted (7). They are found intracellular and 
their activity has been reported in many tissues, but most of their activity was intensively 
studied in the brush border branches of the intestine and kidney (57), (101), the anterior 
pituitary (71), leucocytes (61), erythrocytes (95) and spermatozoids (129) in vertebrates. 
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Plant genomes encode hundreds of proteases which are key regulators of a striking variety of 
biological functions in plants including meiosis, gametophyte survival, embryogenesis, seed 
coat formation, etc.(135). Proteases are also found in microbes like bacteria, fungi and 
viruses with broad biochemical activity and susceptibility to genetic manipulation (116). 
Microbial proteases are preferred than plant and animal proteases, because they possess 
almost all the characteristics required for the biotechnological applications (102). This very 
high extensive presence of proteases in both organs and subcellular compartments suggests 
that they play an important biological role in both physiological and pathophysiological 
conditions of an organism (87). 
Sources of proteases: 
Proteases are ubiquitous, because they are physiologically important for all living organisms. 
They are found in a wide diversity of sources such as plants, animals and microorganisms 
(102). 
Plant proteases: Some of the well-known proteases of plant origin are papain, bromelain, 
keratinases, and ficin. Papain is a traditional plant protease which is extracted from the latex 
of Carica papaya fruits (120). Papain is extensively used in industry for the preparation of 
highly soluble and flavoured protein hydrolysates. Bromelain is obtained from the stem and 
juice of pineapples. Some group of plants produces proteases which degrade hair (102). 
Animal proteases: The well-known proteases of animal origin are pancreatic trypsin, 
chymotrypsin, pepsin, and rennins (13), (47). Trypsin is a serine protease which is an 
important intestinal digestive enzyme responsible for the hydrolysis of food proteins. It is 
also used in the preparation of cell culture media and in some medical applications. 
Chymotrypsin is found in animal pancreatic extract which is activated by trypsin from its 
inactive form called chymotrypsinogen. Chymotrypsin is specific for the hydrolysis of 
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peptide bonds in which the carboxyl groups are provided by one of the three aromatic amino 
acids. Pepsin is an acidic protease present in the stomach. It catalyzes the hydrolysis of 
peptide bonds between two hydrophobic amino acids (102). 
Microbial proteases: proteases can be produced extracellularly and intracellularly by 
microorganisms. Bacteria, fungi and viruses are capable of producing proteases. Microbial 
proteases have more commercial applications than proteases of plant and animal origin. This 
is because of the low yield and difficulty in the production of proteases from plant and animal 
sources. On the other hand the process of protease isolation from animal and plant sources 
requires a series of extraction and purification steps (102). Bacteria and fungi produces 
neutral and alkaline proteases, additionally fungi produces acid proteases. Bacterial and 
fungal proteases are important to the global carbon and nitrogen cycles in the recycling of 
proteins (32). A secreted bacterial protease may also act as an exotoxin, and be an example of 
a virulence factor in bacterial pathogenesis (81). Viral proteases have gained importance 
because of their functional involvement in the processing of proteins of viruses that cause 
certain fatal diseases in animals and humans. Serine, aspartic and cysteine proteases are 
found in various viruses (105). Viral proteases are required for the processing of viral 
polyproteins or the maturational processing of precapsids, and their catalytic activity is 
required for the production of new, infectious virion (132). Now a days an extensive research 
has focussed on the three dimensional structure of viral proteases and their interaction with 
synthetic inhibitors to design potential antiviral drugs. 
Classification and nomenclature: 
              A milestone in the development of any field of study is the existing of a sound 
system of nomenclature and classification for the objects with which it deals. Both 
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nomenclature and classification are essential for information-handling. A better system also 
serves to emphasize important questions and thus provokes new discoveries. 
            Proteases are classified in subgroup 4 of group 3 (hydrolases) by the Nomenclature 
Committee of the International Union of Biochemistry and Molecular Biology (153). 
However general system of enzyme nomenclature does not comply easily for proteases, 
because of their huge diversity of action and structure. Based on three major criteria, 
currently proteases are classified: (i) type of chemical reaction catalyzed by the protease, (ii) 
chemical nature of the catalytic site, and (iii) evolutionary relationship with reference to the 
structure (108), (107). Proteases are subdivided into two major groups, i.e., exopeptidases and 
endopeptidases, based on their site of action. Exopeptidases cleave the peptide bond proximal 
to the amino or carboxy termini of the substrate, whereas endopeptidases cleave peptide 
bonds distant from the termini of the substrate (6). Proteases are further classified into four 
important groups, depending on the functional group present at the active site of the enzyme: 
(i) serine proteases, (ii) cysteine proteases, (iii) aspartic acid proteases, and (iv) 
metalloproteases (40). Apart from these four groups, there are two small groups of proteases 
namely threonine and glutamic acid proteases which were not described until 1995 and 2004, 
respectively. The other four groups of proteases have been intensively studied for both their 
catalytic mechanisms and proteolytic activity (40), (44), (109), and (110). There are few 
proteases which do not precisely fit into the standard classification, e.g., ATP-dependent 
proteases which require ATP for their catalytic activity (79). Proteases are classified into 
different families, depending on their amino acid sequences (4) and further subdivided into 
“clans” to get suitable sets of peptidases that have diverged from a common ancestor (105). 
Classification of proteases by IUBMD (based on the details of the reaction catalyzed) 
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         The term “peptidase” has been suggested by the International Union of Biochemistry 
and Molecular Biology (IUBMB) to represent a subset of peptide bond hydrolyses with code 
E.C.3.4. “Protease” is the word widely used as synonym to peptidase. In 1992 IUBMB 
classified peptidases into two categories: (i) Exopeptidases, and (ii) Endopeptidases (153). 
The IUBMB peptidase/protease classification is shown in the Table 1.1   
Exopeptidases: 
They are classified according to their site of action. They act only near the ends of 
polypeptide chains. Based on their site of action at the N or C terminus, they are classified as 
amino and carboxypeptidases, respectively (6). Aminopeptidases act at a free N terminus of 
the polypeptide chain and liberate a single amino acid residue, a dipeptide, or a tripeptide. 
They are present in a wide diversity of microbial species including bacteria and fungi (114). 
Most of the aminopeptidases are intracellular enzymes, but there is a report on an 
extracellular aminopeptidase produced by Aspergillus oryzae (67). Carboxypeptidases act at 
the carboxyl terminal ends of proteins. Based on the nature of amino acid residues at the 
active site of the enzymes, carboxypeptidases are dived into three major groups, serine 
carboxypeptidases, cysteine carboxypeptidases, and metallo carboxypeptidases (102). 
Endopeptidases: 
Endopeptidases act on the peptide bonds in the inner regions of the polypeptide chain away 
from the N and C termini (6).  The endopeptidases, which cleave peptide bonds at points 
within the protein, are often called as proteinases in the literature (153). These enzymes show 
negative activity in the presence of free amino and carboxyl groups. On the basis of their 
catalytic mechanism, endopeptidases are divided into four sub groups, (i) serine proteases, 
(ii) aspartic proteases, (iii) cysteine proteases, and (iv) metalloproteases (40). 
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            Based on this system of classification, every peptidase is given a single four-number 
code. The codes of proteases that will be discussed on in this dissertation are: Norovirus 3C-
like protease (E.C 3.4.22.66), Poliovirus 3C protease (E.C 3.4.22.28), and Porcine 
transmissible gastroenteritis virus (E.C 3.4.22.69). This classification system provides a 
practical approach for the characterization of new peptidases, without requiring its structure 
information. Enzyme nomenclature has been used for many decades and it depends mainly on 
the reaction catalyzed, but failed to recognize the structural relationship among peptidases 
(153). 
Classification of proteases based on the catalytic or chemical mechanism 
         In 1960, Hartley initiated a series of developments in the protease community that has 
now provided the very useful idea of catalytic type. Based on the mechanisms used in the 
catalysis, proteases are currently classified into six groups namely serine proteases, cysteine 
proteases, aspartic proteases, metalloproteases, threonine proteases, and glutamic acid 
proteases. These proteases are named based on the active amino acid in the catalytic site of 
the protease. For example, cysteine proteases contain a cysteine amino acid residue in the 
active site that acts as nucleophile in the catalytic site of the protease. Among the six groups 
of proteases, only four groups of proteases (serine, cysteine, aspartic, and metalloproteases) 
are extensively studied for both their catalytic mechanisms and proteolytic specificities (40), 
(44), and (109).  
Serine proteases: 
Serine proteases are characterized by the presence of a catalytic triad composed of amino 
acids serine (nucleophile), aspartic acid (electrophile), and histidine (base) in their catalytic 
site. In this case serine acts as a very active residue and forms the covalent bond with the 
substrate (40). These proteases are found among viruses, bacteria and eukaryotes, suggesting 
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that they are important to the organisms. Based on their structural similarities, these proteases 
are grouped into 20 families, which are further subdivided into about six clans with common 
ancestors (108), (107). Most of the serine proteases are active at neutral and alkaline pH, with 
an optimum pH 7 and 9. Based on their structure serine proteases fall into two broad 
categories: chymotrypsin-like and subtilisin-like (73). These proteases are responsible for co-
ordinating various physiological functions in humans, including digestion, immune response, 
blood coagulation and reproduction (44). These proteases can be inhibited by small organic 
compounds (organophosphates, heterocyclic derivatives) or by protein protease inhibitors 
(serpins) (87). 
Aspartic proteases: 
Aspartic acid proteases are also known as acidic endopeptidases. The active site of these 
proteases consists of two aspartic acid residues. These proteases are grouped into three 
families, pepsin (A1), retropepsin (A2), and enzymes from pararetroviruses (A3) (106) (104), 
and have been placed in clan AA. Most of the aspartic acid proteases show maximal activity 
at low pH (pH 3 to 4). The active-site aspartic acid residue is situated within the motif Asp-
Xaa- Gly, in which Xaa can be Ser or Thr. Pepstatin can inhibit the aspartic proteases (30). 
They are also sensitive to diazoketone compounds like diazoacetyl-DL-norleucine methyl 
ester (DAN) and 1,2-epoxy-3-(p-nitrophenoxy) propane (EPNP) in the presence of copper 
ions (102). 
Cysteine proteases: 
Cysteine proteases occur in both prokaryotes and eukaryotes. They are also known as thiol 
endopeptidases and are characterized by the catalytic dyad: cysteine (Cys), and histidine 
(His). In this dyad cysteine is the important active residue which involves in the formation of 
intermediate complex with substrates.  The position of Cys and His (Cys-His or His-Cys) 
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residues differ among the families (107). Cysteine proteases are divided into four groups on 
the basis of their side chain specificity: (i) pepsin-like, (ii) trypsin-like with preference for 
cleavage at the arginine residue, (iii) specific to glutamic acid, and (iv) others. The best 
known cysteine protease is papain. Most of the cysteine proteases are active at neutral pH, 
very few of them are maximally active at acidic pH e.g., lysosomal proteases. Epoxides, 
microbial inhibitors and the compounds that block thiol groups can inhibit the cysteine 
endopeptidases (87). 
Metalloproteases: 
Metalloproteases are diverse of the catalytic types of proteases characterized by the presence 
of a divalent metal ion for their activity (104). These proteases contain a metal ion, generally 
zinc (Zn²⁺) in their active site which is an integral part of the protein structure, while a few 
contain Mg2+, Ni2+, or Cu2+. Catalytic metal ion activates the water molecule, which acts as 
a nucleophile in catalysis. The majority of metalloproteases contain one catalytic metal ion, 
and those containing two catalytic metal ions so far described are all exoproteases (7). In 
addition to a Zn²⁺ ion in the active site, there will be a glutamic acid (Glu), or often 
associated with tryptophan (Trp) or histidine (His) (87). Metalloproteases are produced by all 
species of plants, animals, and microorganisms. Some of them function in the cell or on the 
membrane and some of them are secreted to the periplasm or outside the cell are called 
extracellular metalloproteases. Extracellular metalloproteases in mammals, matrix 
metalloproteases are related to many diseases. Collagenases, some snake venoms and 
thermolysin form bacteria are some of the examples of these proteases (46), (90), (124), and 
(137). They are inhibited by ion-chelating agents, some are inhibited by phosphoramidon. 
Matrix endopeptidases are inhibited by TIMP’s (tissue inhibitors of metallo-endopeptidases) 
and IMP’s (inhibitors of metallo-endopeptidases). The optimum pH for these proteases is 
from 7 to 9 (87).  
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Classification of proteases based on the molecular structure and homology (Barrett & 
Rawlings classification of proteases)  
            In 1993, Neil D. Rawlings and Alan J. Barrett proposed another classification of 
proteases that is based on the relationship between molecular structure functional homology. 
This system mainly depends on the availability of data for amino acid sequences and the 
three-dimensional structures that were developed only in the early 1990s. According to this 
classification system, peptidases are assigned to families and the families are again grouped 
in clans. A peptidase database called MEROPS was launched by Rawlings and Barrett in 
1999 and the classification is also known as “MEROPS classification”. 
           The term “family” defines a group of homologous proteases. Proteases that show 
significant similarity in the amino acid sequence to the type protease of the family or to 
another protein that has been already shown homologous to the type protease are grouped 
into one family. At least the relationship must exist in the peptidase unit. A family can 
contain only one peptidase if no homologues exist, and a single gene product like viral 
polyprotein containing more than one protease can be assigned to a different family. Each 
family is given by a letter representing the catalytic type of proteases (S, C, A, M, T, G or U, 
for serine, cysteine, aspartic, metallo, threonine, glutamic or unknown, respectively) and a 
special number, e.g. S1, M1. Apart from this, some families are even divided into subfamilies 
because there is evidence of a very ancient divergence within the family, e.g. S1A, S1B etc. 
        A “clan” comprises of all the proteases that have been arisen from a single evolutionary 
origin. It describes one or more families that show evidence of their evolutionary connection 
by their similar tertiary structures, or when structures are not available, by the order of 
catalytic-site amino acids in the polypeptide chain and often by common sequence motifs 
around the catalytic amino acids. Each clan is recognized with two letters, the first 
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representing the catalytic type of families included in the clan (with the letter “P” being used 
for a clan containing families of more than one of the catalytic types serine, threonine and 
cysteine). Some families cannot be assigned to clans because of the requirement of formal 
assignment. Such a family is described as belonging to clan A-, C-, S-, M-, T-, G- or U-, 
according to the catalytic type. Some clans are divided into subclans on the basis of the 
evidence of a very ancient divergence within the clan, for example MA(E), the gluzincins, 
and MA(M), the metzincins (105), (7) . 
            The full information about families and clans for MEROPS classification can be 
found at the following linkages, http://merops.sanger.ac.uk/cgi-bin/family_ index?type=p , 
and http://merops.sanger.ac.uk/cgi-bin/clan_index?type=p. The MEROPS Ids of proteases 
that will be focussed on in this dissertation are: norovirus 3C-like protease (C37.001), 
poliovirus 3C protease (C03.001), and TGEV main/3C protease (C30.004). MEROPS 
classification of proteases is showed using aspartic acid and cysteine proteases as examples in 
Table 1.2 
Protease terminology 
         Proteases are macromolecules with a number of atoms and side chains that alters shape 
and charges on their surfaces and/or inside the protein. A protease identifies its peptide 
substrate based on its backbone conformation, amino acid sequence and position of the amide 
bonds being cut. The protease substrate binds to a protease in a complementary manner based 
on size, shape and electrostatics. In 1967, Schechter and Berger proposed a nomenclature of 
protease and substrate that is commonly used to number the active site of a protease. This 
nomenclature states that the amino acid residues of protease substrates are regarded 
comparative to the site of backbone cleavage. The amino acid residues towards the N-
terminal from the cleavage site are said to be on the P side, and those residues towards the C-
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terminal are said to be on the P’ side. Right away N-terminal to the cleavage site is residue 
P1, and moving more N-terminally are residues P2, P3, P4, and so on. Residue right away C-
terminal to the cleavage site is said to be P1’, and moving more C-terminally are residues 
P2’, P3’, and so on. In this way, the protease cleaves the amide bond that links amino acid 
residues P1 and P1’. 
           Proteases contain binding pockets called substrate binding pockets for substrate amino 
acid residues. Those binding pockets that bind to the P side of the substrate are called S 
pockets, whereas those pockets that bind to the P’ side of the substrate are called S’ binding 
pockets. The protease pocket that interacts directly with the P1 amino acid residue of the 
substrate is called S1 pocket and the remaining pockets that bind to residues P2, P3, P4, and 
so on are called S2, S3, S4, and so on respectively. In the same way, the protease pocket that 
interacts directly with the P1’ amino acid residue of the substrate is called S1’ pocket, and the 
remaining protease pockets that bind to residues P2’, P3’, P4’ and so on are called  S2’, S3’, 
S4’ and so respectively. Thus, the amino acid residues involved in the proteolysis are 
positioned between the S1 and S1’ substrate binding pockets. The character of these pockets 
decides the degree of specificity of the protease (120), (141). The substrate and substrate 
binding pockets are shown in figure 1.2 
 Proteases and proteolytic reactions or mechanisms    
         Proteases breakdown peptide bonds between amino acids in proteins and peptides by 
the process of hydrolysis. Even though, they catalyze the same kind of reactions, a large 
number of proteases exist to hydrolyze the specific substrates in the precise biological 
environment. According to MEROPS peptidase database, there are more than 2000 different 
proteases exist. Catalytic mechanisms of four groups of proteases (serine, cysteine, aspartic, 
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and metallo) that are intensively studied for their catalytic mechanism and substrate 
specificity are described below. 
Serine protease catalytic mechanism  
          Serine proteases are enzymes that cleave peptide bonds in proteins, in which serine acts 
as the nucleophilic amino acid at the active site. The active site of serine protease consists of 
three amino acids serine, histidine, and aspartic acid forming a catalytic triad. The basic 
mechanism of action of serine proteases involves transfer of the acyl portion of a substrate to 
a functional group of the enzyme (44). The two basic steps of catalysis by this group of 
enzymes thus include: 
(i) Firstly, the formation of an ester bond between the oxygen atom of serine and the 
acyl portion of the substrate - which produces a tetrahedral intermediate and 
releases the amino part of the substrate; and 
(ii)  Secondly, the attacks of water molecule on the acyl-enzyme intermediate, which 
breaks it down and releases the acidic product - while regenerating the original 
enzyme form (Figure 1.3). 
Cysteine protease catalytic mechanism  
         Cysteine proteases are enzymes that cleave peptide bonds in proteins, in which cysteine 
acts as the nucleophilic amino acid in the active site of the protease. The active site of 
cysteine protease consists of two amino acids cysteine, and histidine forming a catalytic dyad. 
But recently, there are some studies reporting that there is a third amino acid that would be 
potentially glutamic acid in the active site of cysteine proteases (49). The basic mechanism of 
cysteine proteases involve: 
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(i)   The first step is deprotonation of cysteine in the enzyme's active site by an 
adjacent amino acid with a basic side chain, usually a histidine residue. Then, the 
correct positioning of the substrate within the catalytic site cleft brings the scissile 
bond into sufficiently close proximity with the cysteine to facilitate nucleophilic 
attack by the thiolate on the carbonyl C of the scissile peptide to generate an 
unstable, covalently bound tetrahedral intermediate. 
(ii) During nucleophilic attack on the substrate carbonyl group, the shift of negative 
charge onto the carbonyl O favours the formation of oxyanion hole, which helps 
in stabilizing the tetrahedral intermediate formed. 
(iii) Collapse of the tetrahedral intermediate complex is promoted by histidine by 
protonating the substrate amide N. This leads to the release of C-terminal portion 
of the substrate by forming an acyl-enzyme intermediate and the amide product. 
(iv) The N-terminal portion of the substrate is released by the hydrolysis of the acyl-
enzyme, which is achieved by the diffusion of the water molecule into the 
catalytic site that is followed by nucleophilic attack on the substrate carbonyl 
carbon, promoted by histidine and potentially glutamic acid (87), (107) (Figure 
1.4). 
Aspartic acid protease catalytic mechanism        
               Aspartic proteases are a family of proteases that use an aspartic acid residue for 
catalysis of their peptide substrates. Their catalytic site consists of two aspartic acid residues. 
The enzyme-substrate intermediate formation is of the general acid-base type rather than the 
covalent type. The basic mechanism is illustrated in the figure (the model chosen is pepsin): 
(i) The catalytic groups of the two aspartic acid molecules at the active site (aspartic 
acid 32 and 215) are linked through a hydrogen bond. In case of aspartic acid 
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proteases, nucleophilic attack is facilitated by two simultaneous proton transfers: 
the first proton is transferred from a water molecule to the carboxylate ion of 
aspartic acid 32, and the second proton from the carboxyl group of aspartic acid 
215 to the oxygen atom of the carbonyl group of the substrate. These transfers of 
protons lead to the formation of a neutral tetrahedral intermediate. 
(ii) The intermediate is destroyed by the similar dual transfer mechanism, which 
donated a proton to the carboxylate ion of aspartic acid 32, thus hydrolysing the 
C-N bond of the substrate by transferring the proton from aspartic acid 215 
carboxyl group to the nitrogen atom (87), (106) (Figure 1.5). 
Metalloproteases catalytic mechanism  
            Metalloproteases contain a metal ion in their active site, generally zinc (Zn
2+
), which 
is an integral part of the protease. These proteases do not form covalent enzyme-substrate 
complex intermediates. Apart from Zn
2+
 ion, the active site always contains a glutamic acid 
residue (Glu), sometimes associated with tryptophan (Trp) or histidine (His). The catalytic 
mechanism of metalloproteases is shown in the (Figure 1.6). The basic catalytic mechanism 
of metalloproteases involves: 
(i) The nucleophilic attack on the carbonyl carbon by zinc bound to water is 
facilitated by the carboxylate ion of the glutamic acid at the active site. 
(ii) The transfer of proton from the carboxylate ion of the glutamic acid to the 
eliminated NH2R’ group breaks down the tetrahedral intermediate, finally 
releasing carboxylic acid with the aid of water molecule (87). 
          The proteases that will be focussed on in this dissertation are cysteine proteases 
because all the three viral proteases such as norovirus protease, poliovirus protease, and 
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transmissible gastroenteritis virus protease contain cysteine as active nucleophile in the 
catalytic site. 
Proteases as targets in drug discovery 
          Proteases are very crucial enzymes that account for ~2% of the genes in humans, 
infectious organisms like bacteria, viruses, and fungi, and other forms of life. They control 
most physiological mechanisms by regulating the activation, synthesis and turnover of all 
proteins. Thus, they are the central regulators of conception, birth, growth, maturation, 
ageing, diseases and death. Proteases are also important for replication or transmission of 
infectious disease causing agents such as viruses, bacteria, and parasites (1). In case of 
viruses, the proteases are required for the processing of precursor polyproteins to yield 
functional viral proteins and therefore viral proteases presents themselves as potential viable 
targets for the development of antiviral strategies (132). On the basis of their importance in 
health and disease, protease inhibitors have already been developed into blockbuster drugs 
and diagnostics, and many other protease inhibitors are in clinical trials. Many protease 
inhibitors have showed assured therapeutic activities in preclinical trials in animals and in 
early clinical trials in man for viral, bacterial, and parasitic infections (1). For example, many 
inhibitors are developed against HIV proteases and this approach has been one of the primary 
means for treating HIV infections (52), (111). A review on “protease inhibitors in the clinic” 
has summarized many more protease inhibitors in clinical development. 
     The proteases that are focussed in this dissertation are viral proteases from norovirus, 
poliovirus, and porcine transmissible gastroenteritis virus. These three viruses are highly 
contagious and there is a need to develop antiviral compounds against these proteases to 
control the outbreaks and transmissions. Although vaccines are available for poliovirus, there 
is a need for development of antiviral drugs, which is discussed under poliovirus literature 
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review. The additional advantage in developing viral protease inhibitors is that the inhibitor 
can act against proteases of different strains in the same family of virus, thereby not only 
controlling the disease during an outbreak, but also reducing the transmission (146).   
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CHAPTER 2-VIRAL PROTEASES AND DISEASES 
LITERATURE REVIEW 
            Viruses are small infectious agents responsible for causing a variety of serious 
diseases in humans, other animals, and plants. As viruses are clinically and scientifically 
important, they have been under intensive study from a long period of time ever since their 
first isolation about a century ago. Viral infection has become a real global threat. Viral 
infection is not only related to serious human diseases like Swine flu, AIDS, SARS, ebola 
and avian influenza (27), but is also associated with common human diseases including 
common cold, liver carcinoma, chickenpox, shingles, cold sores, gastroenteritis and etc. Viral 
proteases are the main enzymes that are involved in some virus maturation and thus represent 
an attractive target for the development of novel antiviral agents (132). Some viral proteases 
and related diseases are shown in the below Table. 
Viral proteases and their related diseases: 
           Protease               Related diseases 
HIV protease                            AIDS 
Norovirus protease  Acute gastroenteritis 
Poliovirus 3C protease  Poliomyelitis 
TGEV main protease  Severe and often fatal diarrhoea in young 
pigs 
Hepatitis C Virus protease  Liver injury, liver cancer and cirrhosis 
Hepatitis A Virus 3C protease  Acute liver infection 
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               Proteases        Related Disease 
Epstein-Barr virus protease  Lymph proliferative infection 
Rhinovirus 3C protease Common cold     
Cytomegalovirus protease Retinitis 
Dengue Virus NS2B-NS3 protease Dengue fever 
Varicella Zoster virus protease Chickenpox, shingles 
Herpes simplex virus protease Oral lesions, genital herpes 
West Nile Virus NS2B-NS3 protease Encephalitis 
FMDV 3C protease Foot and mouth disease in animals 
  
Norwalk virus  
Noroviruses are the most common cause of epidemic non-bacterial gastroenteritis, 
responsible for approximately 90% outbreaks worldwide, and a major cause of foodborne 
illness (72). In the United States alone approximately 21 million illnesses attributable to 
norovirus are estimated to occur annually and they are responsible for more than 50% of all 
foodborne outbreaks of gastroenteritis (139), (154).  The virus is transmitted by the fecal-oral 
route through contaminated food and water, by direct contact, and possibly by transmission 
through air-borne viral particles. Noroviruses are highly infectious and just a few particles 
can cause infection (21). Outbreaks have been reported in a variety of settings including 
hospitals, military troops, cruise ships, schools, prisons and childcare centres (60). When a 
person becomes infected with norovirus, the virus begins to multiply within the small 
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intestine. After approximately 1 to 2 days norovirus symptoms can appear. The principal 
symptom is acute gastroenteritis that develops between 24 and 48 hours after exposure, and 
lasts for 24 to 60 hours. The disease is usually self-limiting, and characterized by nausea, 
forceful vomiting, watery diarrhea, and abdominal pain; and in some cases, loss of taste, 
general lethargy, weakness, muscle pains, headache, coughs, and low-grade fever may occur. 
The median incubation period is classically 32 hours, with a range of 24-48 hours, but can 
extend outside this range (12-50 hours). Symptoms usually resolve within 24-48 hours but 
may range from 12-72 hours. However, in some people symptoms can last longer than 
previously thought, particularly among the elderly and in young children, as well as among 
transplant recipients and the immunosuppressed, such as people on immunosuppressive 
therapy, or ill with immune-modulating diseases (e.g. HIV) (155). It appears that individuals 
develop short-term immunity following infection and immunity is strain specific. The genetic 
variability in circulating noroviruses indicates that individuals are likely to be repeatedly 
infected during their lifetime. Short-lived immunity may explain in part the high attack rates 
in all age groups in an outbreak (77). There is evidence suggesting to norovirus infection to 
be based on histo-blood group antigens (131). Viral shedding is greatest during the acute 
illness and the amount of virus excreted decreases rapidly with recovery. Viral shedding in 
stools is greatest over the first 24-48 hours (28).  
           Noroviruses are a group of single-stranded RNA viruses that have been classified as 
members of the family Calciviridae (97), (118). Comparisons of genome sequence and 
organization have placed these viruses in the family Caliciviridae: a viral family consisting of 
five currently recognized genera, one of which is noroviruses (91). Noroviruses have been 
subdivided into five genogroups (GI-GV) with the noroviruses infecting humans most 
commonly occuring in genogroups I and II. The GI and GII noroviruses are further 
subdivided into genotypes. For example genogroup II, the most prevalent human genogroup, 
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presently contains 19 genotypes. Genogroups I, II and IV infect humans, whereas genogroup 
III infects bovine species and genogroup V has been recently isolated in mice (100). 
Noroviruses commonly isolated in cases of acute gastroenteritis belong to two genogroups: 
genogroup I (GI) includes Norwalk virus, Desert Shield virus, and Southampton virus and 
genogroup II (GII), which includes Bristol virus, Lordsdale virus, Toronto virus, Mexico 
virus, Hawaii virus and Snow Mountain virus (152). 
          The Norwalk virus (NV) is responsible for an outbreak of non-bacterial gastroenteritis 
in a school in Norwalk, Ohio, in 1968 and it is the first enteric calicivirus discovered in 1972 
using immune electron microscopy (54). The genome of the Norwalk virus is the first to be 
sequenced using hybridization assays (143).  Among all the genogroups of noroviruses, 
Norwalk virus is the most studied prototype virus and is classified as GI/1 strain. In recent 
years, 75-100% of norovirus outbreaks and sporadic cases worldwide are due to the strains 
from genogroup II (92). Globally 60-70% of all norovirus outbreaks are associated with GII/4 
strains (125).  
           Currently, there is no vaccine or antiviral therapy available for the control of norovirus 
infections due to the lack of permissive cell culture systems and animal models for human 
noroviruses. Noroviruses show high genetic diversity, and because of that immunity to one 
strain cannot provide protection from another strain (35). According to National Institute of 
Allergy and Infectious Diseases (NIAID) ,noroviruses are classified as category B pathogens 
due to their highly contagious nature and a potential to cause serious public health issue, 
because as few as 10-100 virions are enough to start infection in a healthy individual (60). 
Hence there is a need for the development of antiviral drugs to control the norovirus 
infections.  
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             Norovirus genome consists of a molecule of single-stranded positive sense RNA of 
approximately 7700 nucleotides with a polyadenylated 3’ terminus (68), (69). These are non-
enveloped viruses. The genome of norovirus consists of three open reading frames (ORFs); 
ORF1 is located towards the 5’ end and encodes a large 200 kDa non-structural precursor 
polyprotein, ORF2 encodes the major capsid protein (VP1), and ORF3 encodes a minor 
structural protein (VP2) which helps in the assembly of newly synthesized viruses (10) 
(Figure 2.1).  
        In vitro translation and mutagenesis studies indicated that the 200kDa ORF1 polyprotein 
of noroviruses (Norwalk virus) is cleaved by the action of a 3C-Like protease to initially 
generate three separate functional protein products. Full processing of the ORF1 precursor 
polyprotein produces six mature non-structural protein products (11), (60) : an N-terminal 
protein (p45), an NTPase (p40), a 3A-like protein (p22), a Vpg protein (p16), the 3C protease 
(p19), and an RNA-dependent RNA polymerase (p57) (Figure 2.2). The protease also allows 
the preferential expression of viral proteins by inhibiting the translation of host proteins by 
cleavage of the poly (A) binding protein (66). The scissile bonds cleaved by the norovirus 
protease within its 200 kDa polyprotein substrate are within the dipeptide recognition 
sequences Glu/Gly or Gln/Gly, where the “/” indicates the cleavage site. The protease 
preferentially cleaves at LQ/GP (p45/p40), LQ/GP (p40/p22), PE/GK (p22/p16), FE/AP 
(p16/p19), and LE/GG (p19/p57) junctions to generate mature proteins (11) (60). The 
protease preferentially accommodates a glutamine residue at the active site S1 position and a 
glutamate residue will also be accepted (38). The catalytic site of Norwalk virus protease 
consists of Cys139, His30 and Glu54 as active amino acid residues. Cys139 acts as 
nucleophile in the active site (Figure 5.1). Norwalk virus protease shows similar 
chymotrypsin-like fold as picornaviral proteases.  
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           Comparative studies of norovirus protease amino acid sequences with those of 
poliovirus (PV), human rhinovirus (HRV), hepatitis A virus (HAV), Chiba virus (CV), 
Southampton virus (SV) and foot and mouth disease virus (FMDV) showed that the 
norovirus protease belongs to the family of chymotrypsin like cysteine proteases because of 
its similarity to picornaviral 3C protease. This is confirmed by the availability of two X-ray 
crystal structures of the protease from group 1 norovirus (85). The active site of cysteine 
proteases generally possess an active site dyad consists of cysteine and histidine, but the three 
dimensional structures of the PV, HRV, HAV, FMDV, CV and SV 3C proteases showed a 
third amino acid in the active site, which may be either aspartate or glutamate (85), (48). 
Since norovirus protease is essential for the processing of the 200 kDa precursor polyprotein 
to produce mature or functional viral proteins, the viral protease presents itself as an 
attractive target for the development of antiviral strategies.  
Poliovirus (PV) 
Poliovirus is a member of the genus Enterovirus, which belongs to the family Picornaviridae. 
The family Picornaviridae is a large family of small, non-enveloped, positive stranded RNA 
viruses which include a number of important human and animal pathogens such as poliovirus 
(PV), hepatitis A virus (HAV), Coxsackievirus (CV), human rhinovirus (HRV) and foot and 
mouth disease (FMDV). The family of Picornaviridae consists of nine genera namely 
Enterovirus, Rhinovirus, Cardiovirus, Aphthovirus, Hepatovirus, Parechovirus, Erbovirus, 
Kobuvirus, and Teschovirus. Polioviruses belong to the genus Enterovirus and the genus can 
be further subdivided into eight clusters consisting of Poliovirus, Human enterovirus A, 
Human enterovirus B, Human enterovirus C, Human enterovirus D, Simian enterovirus A, 
Bovine enterovirus, and porcine enterovirus B (23). Poliovirus, Coxsackieviruses, and 
echoviruses are the major pathological disease causing viruses in the genus Enterovirus. 
These viruses are responsible for causing diseases such as meningitis, encephalitis, 
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myocarditis, paralysis, diarrheic and respiratory diseases (84). Enteroviruses replicate mainly 
in the gastrointestinal tract and an estimated infection per year worldwide is one billion (88).  
          Initially human enteroviruses were classified into four categories based on the clinical 
manifestations observed in human infections and experimentally inoculated mice. The four 
categories are (i) polioviruses, responsible for causing flaccid paralysis in humans but not in 
suckling mice without CD155; (ii) coxsackie A viruses (CAV), related to human central 
nervous system pathology and skeletal muscle inflammation and flaccid paralysis in suckling 
mice; (iii) coxsackie B viruses (CBV), connected with illness of the human cardiac and 
central nervous systems, focal lesions in skeletal muscle, brain, and spinal cord, and as well 
as spastic paralysis in suckling mice; and (iv) echoviruses, not connected with human disease 
nor with paralysis in mice (23). Highly sophisticated techniques available in the field of 
molecular biology lead to the proposal of a new modified classification under which human 
enteroviruses are subdivided into five species consisting of poliovirus, and Human 
enterovirus A, B, C, and D. As polioviruses show greatest similarity of relation to the C- 
cluster human enteroviruses (CAV11, CAV17, and CAV 20) on the basis of genome 
sequences, recently the Executive Committee of the International Committee on Taxonomy 
of Viruses (ICTV) recommended a proposal to move the polioviruses into the Human 
enterovirus C species. In fact polioviruses differ from these three C-cluster coxsackie A 
viruses in the structural capsid region (P1) (16). 
          Poliovirus is responsible for causing poliomyelitis in humans. Poliomyelitis or often 
called polio or infantile paralysis is an acute central nervous system disease. The epidemics 
of the poliomyelitis began to occur in the United States and Europe during the beginning of 
the 20th century (99). In 1840, Jakob Heine first recognised the poliomyelitis as a distinct 
condition (93) and in 1908 poliovirus was identified as the causative agent for poliomyelitis 
by Landsteiner and Popper (99). Even though the epidemics of poliomyelitis began to occur 
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near the beginning of the 20th century, there is an historical record stating that isolated cases 
of poliomyelitis have been occuring for many years (86). Poliovirus shows structural 
similarity with other human enteroviruses (Coxsackieviruses and echoviruses), as well as to 
human rhinoviruses. In common they all use immunoglobulin like molecules to recognise and 
enter into host cells (42). A study of phylogenetic analysis of the RNA and protein sequences 
of poliovirus suggests that, a mutation within the capsid may have helped in the evolution of 
poliovirus from a C-cluster Coxsakie A virus ancestor (51). Based on slight differences in the 
capsid protein, poliovirus is divided into three serotypes, Poliovirus 1 (PV1), poliovirus 2 
(PV2) and poliovirus 3 (PV3). The cellular receptor specificity and antigenicity are 
determined by the capsid proteins. All three forms of poliovirus are highly infectious, but 
among them PV1 is the most infectious form in the nature (93). Wild poliovirus type 1 is 
highly restricted to the regions of India, Pakistan, Afghanistan, and Egypt, but it is highly 
prevalent in West and Central Africa. Wild poliovirus type 2 was last identified in October 
1999 in Uttar Pradesh, India and probably it has been extirpated. Wild poliovirus type 3 is 
confined to five countries during 2004 endemic namely Nigeria, Niger, Pakistan, India, and 
Sudan (58).   
           Poliovirus is an enterovirus and the virus is transmitted person to person by fecal-oral 
route and also oral-oral route. Poliomyelitis is highly contagious and wild polioviruses in 
endemic areas can infect the entire population. Poor living conditions, tropical and 
subtropical conditions, high birth cohorts, and high population compactness are the important 
hazardous circumstances involved in the transmission of poliovirus. When a person becomes 
infected with poliovirus, the replication of virus occurs in the alimentary tract (84), (86), and 
(58). The symptoms are sometimes inconspicuous or only mild. The virus is shed in the feces 
of the infected individual. For any virus, the primary determinant of infections is its capacity 
to enter a cell and generate additional infectious particles. The presence of CD155 receptor 
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on the cells and tissues of humans and a few subhuman primates (chimpanzees and Old 
World monkeys) is an opinion to state that, the virus can infect those cells and tissues. But 
however, poliovirus is strictly a human pathogen and does not naturally infect any other 
species, even though subhuman primate species can be experimentally infected (99), (84), 
and (83). In most of the cases of poliovirus infection, 95% of cases show only a primary, 
temporary presence of viremia and the poliovirus infection may be asymptomatic. In some 
cases, about 5% the virus enters and multiplies in other places such as brown fat, 
reticuloendothelial tissue and muscle. The prolonged viral multiplication gives raise a 
condition called secondary viremia, which leads to the advancement of onset symptoms such 
as fever, headache and sore throat (117). Less than 1% of poliovirus infections lead to 
paralytic poliomyelitis, the condition in which the virus enters the central nervous system and 
replicates in motor neurons within the spinal cord, brain stem. The symptoms of paralytic 
poliomyelitis include an asymptomatic phase of 1-3 days, followed by acute onset of flaccid 
paralysis with fever. Depending upon the site of viral replication in the central nervous 
system, the paralytic poliomyelitis may affect skeletal muscles causing spinal poliomyelitis, 
respiratory muscles causing bulbar poliomyelitis, or may affect both muscles causing bulbo-
spinal poliomyelitis. The loss of motor neurons leads to temporary or permanent paralysis 
(58). 
            Poliomyelitis is a seasonal disease with high transmission rates during summer and 
autumn and low transmission rate in winter. Paralytic assail is based on the serotype and wild 
poliovirus type 1 is connected with highest rates of paralytic attack (~0.5%) and lowest rates 
of paralytic attack are connected with poliovirus type 2 (˂0.05%). The paralytic attack of 
poliovirus is thought to be rare and an accidental distraction of gastrointestinal infection (84). 
The process by which the virus reaches the central nervous system is insufficiently 
understood. Three non-mutually exclusive hypotheses have been propounded to explain the 
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process of entry of poliovirus into the central nervous system. Primary viremia is common in 
all the three theories. The first theory states that the virus may enter the central nervous 
system from the blood by crossing over the blood brain barrier, without the influence of its 
receptor CD155 (149). The second hypothesis, explains that the virus is transported to the 
central nervous system ascending from the muscle to the spinal cord and brain through nerve 
pathways by retrograde axonal transport (89), (112). The third hypothesis, explains that there 
may be a chance of spreading the virus to the central nervous system by infected primary 
monocytes or macrophages expressing CD155 (23).  
         The genome of poliovirus is approximately 7400 nucleotides in length and composed of 
single stranded positive sense RNA consisting three physically separate regions. A relatively 
long 5’ non translated region (5’NTR) of 742 nucleotides , a single open reading frame 
(ORF) which codes for a polyprotein of 2209 amino acids and a considerably short 3’ non 
translated region (3’ NTR) of 70 nucleotides followed by a virus-encoded poly(A) tract of 60 
adenine residues length (25), (62), (98), and (128). The 5’ NTR region of the poliovirus 
genome is subdivided into (i) 5’ terminal clover leaf, which acts as an indispensable cis-
acting factor in viral replication and in regulating the process of translation initiation; and (ii) 
the internal ribosome entry site (IRES), for its propensity to initiate the process of cap-
independent translation of the viral mRNA regardless of its location within an RNA molecule 
and even a free 5’ end (84), (23). Comparatively there is less known about 3’ NTR in contrast 
to 5’ NTR. The 3’ NTR region is polyadenylated and there is evidence that it has an 
important role in RNA replication. The deletion of the 3’NTR showed only minimum effects 
on the propagation of poliovirus in HeLa cells. But in the cells of neuronal origin, the ability 
of the virus propagation is evidently reduced both in vitro and in vivo (16), (15). The 250 
kDa polyprotein is encoded by the single open reading frame (ORF). The single open reading 
frame (ORF) can be subdivided into regions P1, P2, and P3, which encodes the structural and 
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non-structural proteins. The unstable polyprotein is cleaved by the proteolytic activity of 
virus-encoded proteases, 2Apro and 3C/3CDpro in cis and trans, finally producing the 
functional proteins required for viral proliferation (39) (Figure 2.3).  
         Poliovirus life cycle occurs within the limits of the cytoplasm of infected cells. 
Attachment of the poliovirion to its cell surface receptor, the human poliovirus receptor 
(hPVR) or CD155 initiates the life cycle of poliovirus (63), (78). Binding of poliovirus with 
CD155 provides an irreversible conformational change in the viral particle required for its 
entry into the cell (55), (145). The definite mechanism used by the poliovirus to release its 
genomic RNA into the infected host cells is not well established. Once the virus is attached to 
its cell surface receptor CD155 on host cell membrane, the process of release of viral 
genomic RNA into the host cell is thought to occur by one of the two pathways: (i) RNA is 
injected into the host cell cytoplasm through the formation of a pore in the plasma membrane; 
or (ii) the virus is taken up by receptor-mediated endocytosis, because the virus can be found 
on endosomes (23). The latter hypothesis is supported by experimental evidence and it 
suggests that the virus particle binds with CD155 and is taken up via endocytosis. Once the 
virus is internalized, the genomic RNA is released (14).  
         When a cell is infected with poliovirus, the genomic RNA is released into the cytoplasm 
of the host cell. This virion RNA functions as messenger RNA and is translated into a single 
autocatalytic polyprotein. The proteolytic cleavage products of this polyprotein serve as 
capsid precursors and replication proteins (140).  Poliovirus shows a certain degree of 
posttranslational control of the amounts of viral proteins generated via an intricate cascade of 
fast and slow proteolytic cleavages by its three proteases 2Apro, 3C/3Dpro (84). Both 2Apro 
and 3Cpro are autocatalytic in nature and they can release themselves from the polyprotein by 
self-cleavage (136). Once the process of translation is completed, the processing of 
polyprotein takes place in three stages. First, P1 precursor is released from the nascent P2-P3 
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protein by 2Apro in a cis-cleavage manner. Second, 3CDpro releases the P3 from the 
remaining protein through cis-cleavage (70). The non-structural proteins 2A, 2BC, 3AB, 2B, 
2C, 3A, 3B (VPg), 3Cpro, 3Dpol and the capsid proteins VP0, VP1, and VP3 are released 
from their precursors by the trans-cleavage action of the 3CDpro. The 3Cpro encoded by 
poliovirus carries out a main cleavage between 2C and 3A (fig). Specifically 3Cpro/3CDpro 
cleaves at a Glutamine-Glycine pair, whereas, 2Apro cleaves at a Tyrosine-Glycine pair (84). 
Other than polyprotein processing, 2Apro is involved in shutting off the cap-dependent host 
cell translation by cleaving the complex eIF-4F and 3Cpro inactivates transcription factor 
TFIIIC and cleaves the TATA box binding protein, there by inhibiting the cellular 
transcription (20), (64).  
           The poliovirus 3Cpro is the most specific of its class, cleaving solely at 
glutamine↓glycine amino acid pairs (“↓” indicates the cleavage site). The refined X-ray 
crystallographic structure of poliovirus 3C protease was determined by Mosimann et al in 
1997. Comparative crystal structural analysis of 3C proteases from hepatitis A virus (HAV), 
human rhinovirus (HRV), and poliovirus (PV) showed that these proteases show a two-
domain β-barrel fold similar to that of chymotrypsin supporting the fact that these viral 
proteases are basically different from that of classical cysteine proteases, like papain (119). 
The 3C protease of poliovirus consists of two six-stranded antiparallel β-barrel domains and 
it shows structural similarity to the chymotrypsin-like serine proteases. The translated 
polyprotein is proteolytically cleaved at 9 of 12 specific processing sites by poliovirus 3C 
protease and is mainly responsible for the production of separate gene products. The shallow 
active site cleft of the poliovirus 3Cpro is larger than the active sites of the chymotrypsin-like 
serine proteases and it is located at the junction of the two β-barrel domains. The active site 
of poliovirus 3C protease consists of a catalytic triad formed by Cys147 which acts as 
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nucleophile, His40 which acts as general acid/base catalyst and Glu71 (Figure 5.2). The 
oxyanion hole consists of the residues Gly145, Gln146, and Cys147 (65), (82).  
            Although poliovirus infection is no longer a major public threat in the developed 
world, poliovirus continues to be one of the extremely studied and most excellent understood 
model viruses to date (84). The poliovirus field is lucky to have more than one excellent 
vaccine, because both of these vaccines showed their potency in the production of anti-
poliovirus antibodies which provides protection from the disease (74). The first polio vaccine 
was developed in 1955, namely Salk polio vaccine or inactivated polio vaccine (IPV) by 
Jonas Salk on April 12. IPV was shown to effectively immunize and protect against 
poliomyelitis. Then, in 1963 the live attenuated oral polio vaccine (OPV) or Sabin polio 
vaccine was developed by Albert Sabin which was demonstrated to be both safe and effective 
(23). Both of these vaccines have their own advantages and disadvantages. In 1988, a 
partnership led by the World Health Organization (WHO), Rotary International, the US 
Centers for Disease Control and Prevention (CDC) and the United Nations International 
Children’s Emergency Fund (UNICEF) launched a project to eradicate poliovirus from the 
world namely The Global Polio Eradication Initiative (GPEI). By the end of 2007, the 
numbers of poliomyelitis cases were almost reduced and only four countries Afghanistan, 
India, Nigeria, and Pakistan, remain with endemic poliovirus transmission (22).  
           The Global Polio Eradication Initiative (GPEI) is highly depended on oral polio 
vaccine (OPV), which is economical and easily administered live, attenuated vaccine. Even 
though OPV is normally safe and effective, in some parts of India, especially in Uttar Pradesh 
and Bihar, it failed to provide protection against poliomyelitis. OPV itself can cause vaccine-
associated paralytic polio (VAPP) about 1 in 750,000 vaccines (130). Generally, healthy 
vaccinated individuals can excrete the OPV viruses in the stool for up to 8 weeks and these 
vaccine derived polioviruses (VDPVs) circulating among non-immune persons in poorly 
30 
vaccinated communities have the capacity to produce neurovirulence and cause poliomyelitis 
(76). IPV is safer than OPV and it does not carry any risk of generating VDPVs or causing 
poliomyelitis. But it is much more expensive than OPV and this will create a problem to its 
universal use by the world’s poorest countries. IPV must be administered parenterally and to 
induce humoral immunity, it requires a minimum of two doses that are spaced ideally at least 
2 months apart, and it will not provide sufficient mucosal immunity to protect against 
poliovirus replication and virus shedding and transmission. IPV is far from ideal, because it 
may require altered dose regimens, adjuvants to improve its effectiveness and alone it is not 
sufficient to control an outbreak (22). Hence there is a clear need to develop new weapons 
with increased ability and effectiveness to control a polio outbreak in the post-eradication era. 
Development of antiviral drugs is an excellent solution to control the poliovirus outbreaks. 
Recently, National Research Council (NRC) conducted a workshop on considering the role of 
antiviral drugs in a polio outbreak entitled “Exploring the Role of Antiviral Drugs in the 
Eradication of Polio”. According to the report presented by NRC, the estimated cost of first 
antiviral drug development will be $75 million which is very less when compared to the 
money spent on the GPEI (approximately $5.3 billion) and it is estimated that about $2 
billion more will be needed to finish the project. Development of antiviral agents for polio 
depicts an excellent cost-effective constituent to assure a successful reverts on investment 
(22). 
            The concept of antiviral therapy is not new for poliovirus infection. This concept of 
antiviral treatment for poliovirus infection became faded by the development of polio 
vaccines. Later in the 1950s, after the achievement of poliovirus propagation in cell culture, 
many compounds supressing the in vitro poliovirus replication were identified (17). Even 
though the idea of antiviral therapy is not new for polio field, but the use of antivirals for 
polio is new, which has successfully achieved vaccination over the past 50 years. One such 
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antiviral target for poliovirus is 3C protease. The 3C proteases of picornaviruses have been 
recognised as targets for the structure-based drug design, because they are responsible for the 
majority of cleavage events (65). Recently one class of inhibitor was developed with a 
Michael-acceptor group at its C-terminus which bounds irreversibly to the catalytic cysteine 
leading to the inhibition of human rhinovirus 3C protease activity not only in vitro but also in 
vivo (48). Since 3C protease of poliovirus is essential for the processing of precursor 
polyprotein to produce mature or functional viral proteins and also to inhibit the cellular 
transcription, the 3C protease of poliovirus presents itself as an attractive target for the 
development of antiviral drugs. 
Transmissible gastroenteritis virus (TGEV)  
           Transmissible gastroenteritis virus (TGEV) is the main cause of gastroenteritis in pigs 
and piglets. Transmissible gastroenteritis (TGE) is considered as highly infectious disease in 
pigs, because of its high mortality rate in young piglets (33). TGEV is an enterophathogenic 
coronavirus (CoV) of the family Coronaviridae with in the order Nidovirales. The order 
Nidovirales is comprised of two families, namely (i) Coronaviridae, and (ii) Arteriviridae, 
which all commonly synthesize a nested set of multiple subgenomic mRNAs. The members 
of family Arteriviridae are known only to infect animals. The family Coronaviridae is 
comprised of two genus (i) Torovirus, and (ii) Coronavirus of similar genome organization 
and replication strategies with different virus morphology and genome length. Coronaviruses 
are responsible for common cold in humans after rhinoviruses and they are known to cause 
economically important diseases in cattle, poultry, pigs and serious disease in cats (80). In 
humans, apart from common cold, coronaviruses cause a notable portion of upper and lower 
respiratory tract infections, which includes bronchiolitis, and pneumonia. Most of the animal 
coronaviruses are associated with enteric and respiratory diseases in livestock and domestic 
animals, resulting in considerable economic losses worldwide (147). The first coronavirus 
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isolated was infectious bronchitis virus (IBV) in 1930s, which is followed by the isolation of 
mouse hepatitis virus (MHV), and transmissible gastroenteritis virus (TGEV) in 1940s (33), 
(8).  
         Serologically coronaviruses are classified into three distinct groups. To date,        
serogroups I and II are known to infect mammals and serogroup III is known to infect birds 
(36). Serogroup I contains the prototypes HCoV-229E, HCoV-NL63, and many animal 
coronaviruses. Serogroup II contains prototypes like MHV, SARS-CoV, and multiple animal 
viruses. Naturally, many coronaviruses are known to infect only one animal species or very 
few related species. SARS-CoV is exempted from this rule, because it is known to infect a 
broad range of mammals, including humans, nonhuman primates, Himalayan palm civets, 
raccoon dogs, cats, dogs, and rodents (37), (113). 
        Coronavirus infection induces a variety of cytopathic effects (CPEs), depending on the 
virus strains and host cells. When a pig or piglet is infected with TGEV, the virus replicates 
in the cytoplasm of absorptive epithelial cells located in the villi of the small intestine and to 
a lesser extent in the respiratory tract (94), (59). TGEV transmission occurs orally and the 
virus is shed in the feces and in respiratory discharges of infected animals. TGEV appears in 
two clinical forms namely epizootic and enzootic. The replication of TGEV in its epizootic 
form results in the degeneration or shortening of the small intestinal villi. This reduces the 
absorptive capability of small intestinal villi, which results in severe watery diarrhea causing 
piglets to die of dehydration during the first two or three weeks of age. TGEV diarrhea in its 
enzootic form generally occurs in piglets older than two weeks of age and can persist through 
two weeks post weaning. This persistent infection of a herd with TGEV is the result of 
introduction of susceptible animals into the immune or partially immune herd (29), (31). 
TGEV is considered as prototypical enterophathogenic virus and often, it is used as a model 
in the studies of pathophysiology and pathogenesis of viral diarrhea (94). 
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         Coronaviruses are also susceptible to mutations at high frequency like other RNA 
viruses, because of the high error frequencies of the RNA polymerases which leads to the 
origin of multiple mutant virus strains. Deletion mutants also arise frequently and the 
emergence of porcine respiratory coronavirus (PRCoV) from TGEV is the best example for 
deletion mutant (59). PRCoV emerged as a new virus during early 1980s in the Europe that 
caused widespread epizoonotic respiratory infections in pigs (103). PRCoV is a spike (S) 
gene deletion mutant of TGEV and the comparison of two strains suggest that tropism and 
pathogenicity are influenced by S gene product (spike protein) and ORF3 (59). The 
replication of PRCoV has been found to occur in nasal, tracheal, bronchial, bronchiolar and 
alveolar epithelial cells and in alveolar macrophages. PRCoV has also been detected in the 
United States and was first isolated in 1989 by Dr. Howard Hill (5). European and US 
PRCoV isolates differ slightly in their S gene and ORF3a deletions.  Clinically PRCoV is 
non-pathogenic and field experiences have shown that herds exposed for the first time have 
no symptoms of disease, but however it affects lung tissue in the presence of other respiratory 
pathogens (156). TGEV infection starts with the binding of virus to the cellular receptor 
porcine aminopeptidase N (pAPN) through its spike (S) protein. In addition to its pAPN 
binding site, spike protein of TGEV has sialic acid binding activity located on the N-terminal 
region of the protein. Virus mutants lacking this sialic acid binding activity did not infect 
piglets showing that binding to sialoglycoproteins or mucins in the gastrointestinal tract is 
important for TGEV to reach the pAPN (24), (122), (9), and (123). As PRCoV is the spike 
gene deletion mutant of TGEV, it cannot infect the intestines of piglets. There is a study 
showing that PRCoV induces partial cross-protective immunity against the TGEV 
transmission in herds (59). Apart from mutations, another common feature of coronavirus 
genetics is high frequency of RNA recombination in all groups of coronavirus, including 
murine hepatitis virus (MHV), TGEV, and IBV. The usage of vaccines against IBV was 
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limited, because of the emergence of IBV variant strains from the recombination of vaccine 
and wild-type virulent strains (147). 
          Currently, there are no vaccines or antiviral therapy available for the control of human 
coronaviruses, but vaccines against common animal coronaviruses, such as IBV and CCoV, 
are generally used to prevent serious diseases in juvenile animals, and efforts are being made 
to improve the efficacy of these vaccines. In case of SARS-CoV, a variety of vaccines were 
developed using inactivated whole virus, expressed proteins, and live virus vectors and they 
all shown to induce the production of neutralizing antibodies in vitro. In animal models, they 
all have shown to decrease the viral replication and inflammation. In case of TGEV, priming 
of piglets with PRCoV acts as a naturally attenuated vaccine, because they both share 90% of 
homology in their genome sequence other than the absence of spike protein in PRCoV. This 
absence changes the infectivity of PRCoV from TGEV and PRCoV is no longer 
enterophathogenic (146), (80). There are several problems associated with coronaviruses, 
even though vaccines are developed against IBV, CCoV, and TGEV. Hence there is a need 
for the development of antiviral drugs to control the coronavirus infections. At molecular 
level, coronavirus infection is well understood by the availability of highly sophisticated tools 
and techniques in the field of molecular biology. It suggests that a number of factors like 
RNA-dependent RNA polymerase, virus encoded proteases, cellular receptors for binding 
and infection, and viral spike glycoprotein can be used as targets for the development of 
antiviral agents (147).  
          By taking the above discussed issues into consideration, it is better to develop broad 
spectrum antiviral drugs against the all existent pathogenic coronaviruses. However, it is not 
easy to develop broad spectrum inhibitors, because the development of broad spectrum 
antiviral agent is completely dependent on the availability of a conserved target within the 
entire coronavirus genus. Some of the key factors like structural proteins (S-spike, E-
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envelope, M-membrane, HE-hemagglutinin esterase, and N-nucleocapsid) show considerable 
diversity among the coronaviruses and they are not suitable for the development of broad 
spectrum antivirals (142), (134), (75), and (115). Apart from structural proteins, the RNA-
dependent RNA polymerase, RNA helicase, and Main protease (Mpro) are the excellent non-
structural protein targets for the development of antivirals. There is no structural evidence 
available for the RNA-dependent RNA polymerase and RNA helicase proteins, enhancing the 
obstacle for designing a versatile antiviral against all coronaviruses (147). Main protease 
(Mpro) or 3C-like protease of coronaviruses can be considered for the development of 
antiviral drug, because of its main role in the viral replication and transcription (151). Among 
the three groups of genus coronavirus, structures of main proteases (Mpros) from TGEV, 
HCoV-229E (group I), SARS CoV (group II), and IBV (group III) are available and the 
substrate-binding pockets present in the cleft between domain I and domain II, and 
particularly S4, S2, and S1 are greatly conserved among coronaviruses Main proteases (144), 
(3), (2), (148), and (147). 
          Coronavirus genome consists of a molecule of single-stranded positive-sense genomic 
RNA of 27 to 31kb in size with a polyadenylated 3’ terminus. Coronaviruses have the largest 
viral RNA genomes known to date and in case of TGEV it is 28,500 nucleotides in length (3), 
(2). They are spherically enveloped viruses of about 100 to 160 nm in diameter. Coronavirus 
genomic RNAs are capped that can serve as mRNAs and the purified genomic RNA can be 
infectious (80). A leader sequence of 65 to 98 nucleotides is present at the 5’ end of the 
genome and that is also seen at the 5’end of all subgenomic RNAs. Leader sequence is 
followed by an untranslated region (UTR) of 200 to 400 nucleotides in length. There is 
another UTR of 200 to 500 nucleotides at the 3’ end, followed by poly (A) of variable length 
(Figure 2.4).  
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          The genome of coronavirus consists of 7 to 14 open reading frames (ORFs) (80). The 
replicase gene encodes the viral proteins that are essential for TGEV replication and 
transcription. Two replicative overlapping polyproteins, ORF1a or pp1a (447kDa) and 
ORF1b or pp1b (754kDa) are encoded by this replicase gene, which are processed by virus-
encoded proteases to generate the functional proteins (2). This process of polyprotein 
processing is mainly achieved by the 33.1 kDa viral cysteine protease, alternatively called 
3C-like protease or main protease (Mpro) (3). Other than this Mpro, most of the 
coronaviruses, with exception to IBV and SARS CoV, encode two papainlike proteases in 
ORF1a to process the N terminal portion of ORF1a (80). Coronavirus main protease is so 
called as 3C-like protease, because of the similar substrate specificities between coronavirus 
Mpro and picornaviral 3C proteases (3Cpro) and the presence of cysteine as the active amino 
acid in the catalytic site. However, there are structural dissimilarities between the proteases of 
the two families (2), (151). The replicase polyproteins are cleaved by the Mpro at no less than 
11 conserved sites involving Leu-Gln ↓ (Ser, Ala, Gly) sequences (“↓” indicates the cleavage 
site). This process is initiated by the autoproteolytic cleavage of Mpro from the pp1a and 
pp1b (45), (26). The crystal structure of coronavirus proteases from TGEV, HCoV-229E, 
SARS CoV and IBV shows that the molecule comprises of three domains. Domains I and II 
contain six-stranded antiparallel β barrels and domain III contains a cluster of five helices (3), 
(144), (2), and (148). The catalytic site of coronaviruses Mpro consists of cysteine and 
histidine residues, which is conserved in all coronaviruses. The catalytic site of TGEV Mpro 
is comprised of Cys144 and His41 (Figure 5.3). These proteases show well defined substrate 
specificities and all known cleavage sites of the proteases contain bulky hydrophobic residues 
mainly leucine at the P2 position, glutamine at the P1 position, and small aliphatic residues at 
the P1’ position. A unique feature found in coronavirus Main proteases is the presence of a 
37 
large C-terminal domain of ~100 amino acid residues that is not found in any other RNA 
virus 3C-like proteases (3), (2).  
            To date, there is no inhibitor for TGEV Mpro has been developed other than the 
existing PRCV attenuated vaccine. Besides this efficacious TGEV vaccine, the development 
of an antiviral drug with wide range spectrum is very useful, because the developed wide 
spectrum antiviral agent can be used to control all coronavirus infections. At the same time, 
the antiviral product is not only useful to control the new virulent forms that evolve from the 
existing viruses, but also to reduce transmission. Since coronavirus (TGEV) Mpro is essential 
for the processing of the two immature polyproteins to produce mature or functional viral 
proteins that are required for viral replication and transcription, the Mpro presents itself as an 
attractive target for the development of antiviral drugs. 
               Among many virally encoded components, viral proteases play an important role in 
the process of virus replication and transcription that are essential for the development of new 
virions. Viral proteases present themselves as key targets for the development of antivirals. 
To characterize the proteolytic activity of these viral proteases, a fast, convenient, continuous 
assay with rapid screening of possible inhibitors is needed.  
               Earlier, the proteolytic activities of viral proteases were conducted by substrate-
analog peptide cleavage assays using conventional HPLC methods (19), (49). These methods 
are highly time consumable and they require skilled personnel to analyse the data. Hence 
there is a need for an alternative method that will greatly facilitate large scale screening of 
potential inhibitors targeting viral proteases without time consuming. One such assay is 
fluorescence resonance energy transfer (FRET) protease assay, which has been developed 
and successfully applied for various cellular and viral proteases including severe acute 
respiratory syndrome coronavirus (SARS CoV), foot-and-mouth disease virus (FMDV), and 
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transmissible gastroenteritis virus (TGEV) (49), (19), and (147). The results obtained from 
the FRET based assay are more sensitive and less time-consuming compared with the RP-
HPLC method. In FRET based assays, a substrate is designed based on a sequence that is 
recognized and cleaved by the protease and the protease activity is successfully monitored. In 
this FRET assay system, substrates are designed in such a way that they have a fluorescence 
donor on one side of the cleavage site, and a fluorescence quencher on the other side of the 
cleavage site. EDANS/DABCYL is the commonly used pair, because of the excellent energy 
overlap of the donor and acceptor (49). In the uncleaved substrate, the donor fluorescence 
signal is quenched by the nearby fluorescence quencher. Once, the donor and quencher are 
physically separated by cleavage in the presence of protease, the donor fluorescence is no 
longer quenched, thereby increasing the fluorescence yield of the donor group. The 
proteolytic activity can be checked in this way by measuring the increase of fluorescence 
with time. The cleavage of the substrates can be inhibited by the addition of protease 
inhibitors to the assay that gives reduced fluorescence intensity (Figure 2.5). This is achieved 
by the saturation of protease catalytic site with inhibitors. Thus, FRET assay provides rapid 
screening and identification of potential protease inhibitors. This assay system is also useful 
in measuring the activity and substrate specificity of a protease.  
             To date, most of the information available on the proteolytic processing of norovirus 
proteases is obtained using in vitro transcription-translation assays (38), (121), and (126) and 
a very few studies are reported on the kinetics of group I norovirus proteases using 
Fluorogenic (127) and chromogenic substrates (48). However, a fast, convenient, and 
continuous assay like FRET that would permit the rapid screening of possible protease 
inhibitors has not yet been reported for proteases from noroviruses GI and GII (150). In the 
case of picornaviral proteases, FRET based assays have been successfully used to monitor 
poliovirus 3C protease, foot-and-mouth disease virus 3C protease, and hepatitis A virus 3C 
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protease (49), (50), (138), and (41). Whereas in the case of coronavirus Mpro, FRET based 
assays were successfully used for monitoring SARS CoV, TGEV, HCoV-229E, FIPV, MHV, 
and IBV (19), (12), (53), (146), and (147). 
Purpose of the study 
The purpose of this study was to characterize the enzymatic activity of related proteases from 
Norwalk virus, poliovirus, and transmissible gastroenteritis virus by using fluorescence 
resonance energy transfer (FRET) technique. These proteases share several common 
characteristics including a typical chymotrypsin-like fold, a Cys residue as a nucleophile in 
the catalytic triad (or dyad) composed of Cys, His, and Glu (or Asp) residues, and preference 
for Glu or Gln residue at the P1 position on the substrate. As these proteases cleave the 
polyprotein of viruses into non-structural functional proteins that are essential for virus 
replication and production of new virions, the viral proteases presents themselves as an 
alluring target for the development of antivirals. To conduct such type of research, it is very 
important to optimize the assay buffer conditions to characterize the enzymatic activity of 
proteases. So, first our aim is to optimize the assay conditions of the FRET assay for each 
virus protease and then second, to study the inhibitor profiles of each virus protease using 
five commercially available standard protease inhibitors (chymostatin, leupeptin, antipain, 
TPCK, and TLCK).  
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CHAPTER 3-MATERIALS AND METHODS 
The expression and purification of proteases from Norwalk, polio and transmissible 
gastroenteritis viruses: 
A full-length codon-optimized cDNAs corresponding to the total amino acid sequence of 
Norwalk virus protease (NVpro),  poliovirus protease (PVpro),  transmissible gastroenteritis 
virus protease (TGEVpro) were cloned into the pET28a vector (GenScript, Piscataway, NJ). 
The synthesized cDNA sequences include start and stop codons as well as sequences 
encoding N-terminal six His amino acid residues for Ni column purification. The plasmid 
carrying a gene sequence that encodes Norwalk virus protease or poliovirus protease or 
transmissible gastroenteritis virus protease was transformed into E.coli BL21 cells.  
Transformation of pET28a vector into the BL21 cells: 
Transformation is the process of introducing foreign DNA into the bacterial cells. A volume 
of 12.5μl thawed BL21 cells were taken in four pre-chilled 1.5 ml eppendorf tubes. To each 
tube one clone of 5μl pET28a vector carrying amino acid gene sequence for Norwalk virus 
protease, poliovirus protease, TGEV protease were added and mixed very gently. The cells 
are incubated on ice for 30 minutes. After 30 minutes of incubation on ice, the cells were 
subjected to heat shock at 42 ˚C by placing the tubes in a water bath for 45 to 60 seconds. 
The tubes are immediately transferred on to ice and kept on ice for 2 to 3 minutes. A volume 
of 250μl pre warmed SOC medium at 37 ˚C was added to the cells and incubated at 37 ˚C for 
one hour in a shaker incubator. 
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Small scale protein expression:  
Small scale protein expression is useful in testing the cells whether they are producing the 
protein of interest or not. So to perform small scale protein expression, after one hour of 
incubation at 37 ˚C, 250μl of transformed cells carrying a recombinant plasmid containing 
gene sequence that encodes for NV protease,  PV protease, TGEV protease were transferred 
into a 10 mL LB broth. To this 10 ml LB broth a volume of 10μl kanamycin antibiotic 
(50mg/ml) was added. This LB broth with transformed cells is placed in a shaker incubator at 
37 ˚C for an overnight culture. Next morning 5 mL of culture from the tube was replaced 
with 5 ml of LB broth and 5μl of kanamycin antibiotic and again placed at 37 ˚C in a shaker 
incubator for one hour incubation. Meanwhile four 250 ml sterile conical glass flasks were 
taken and 50 ml of LB broth and 50 μl of kanamycin antibiotic (50mg/ml) is added to each 
flask and placed in a shaker incubator at 37 ˚ C for pre-warming the medium before 
inoculating with culture. After one hour of incubation, 1 ml of culture was added to the pre-
warmed 50 ml medium and optical density readings were noted at 600nm using 
spectrophotometer. When the optical density of the culture reached 0.4, one ml of uninduced 
samples were collected in a 1.5 ml eppendorf tubes before inducing with 1mM final 
concentration of isopropyl β-D-thiogalactopyranosie (IPTG). A volume of 500 μl of IPTG 
was added to 50 ml of culture medium. The induced cultures are kept at 37 ˚C for 4 hours in a 
shaker incubator.  
SDS-PAGE analysis: 
The uninduced samples are centrifuged at 12,000 rpm for one minute and the pellets are 
collected by discarding the supernatant carefully. The uninduced pellets are carefully 
resuspended with 250 μl of 1X LDS buffer and sonicated. After 4 hours of induction, the 
induced cultures are centrifuged at 3000 rpm for 5 minutes. The supernatants were discarded 
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and the pellets are carefully resuspended with 250 μl of 1X LDS buffer and sonicated. Make 
sure that sample tubes are on ice while sonication. After sonication, samples were heated at 
95 ˚ C for 3 minutes before loading on to the SDS-PAGE gel. A volume of 15 μl of samples 
was run across a volume of 5 μl EZ-marker ladder. When the samples were fully run, the gel 
was washed three times with double distilled water for 5 minutes each time and stained with 
Simply blue for an hour by placing it on shaker. After one hour of staining, the gel was 
destained with double distilled water by placing it on shaker.  
Large scale protein expression:  
The process for large scale protein expression is also similar to small scale expression other 
than the quantity of protein expressed. In large scale protein expression, for overnight culture, 
20 ml of LB broth and 20 μl of kanamycin antibiotic (50mg/ml) are taken in a 50 ml tube, 
inoculated with BL21 cells carrying recombinant plasmid vectors (pET28a) containing genes 
that code for proteases of interest (Norwalk virus protease or poliovirus 3C protease, or 
TGEV main protease), and kept in a shaker incubator at 37 ˚ C for overnight. Next day, 10 ml 
medium from the overnight culture was pipetted out and replaced with10 ml of new LB 
media and 10 μl of kanamycin (50mg/ml) was added and placed again in shaker incubator at 
37 ˚ C for one hour incubation. Meanwhile four large 2 liter sterile glass flasks were taken 
and to each flask, 200 ml of sterile LB media and 200 μl of kanamycin are added. These 
flasks were kept in a shaker incubator at 37 ˚ C for pre-warming the media before inoculation 
with overnight culture. After one hour of incubation, 5 ml of overnight culture was added to 
each large flask and optical density (OD) readings were measured at 600 nm using 
spectrophotometer. When the optical density value reached 0.4, each flask was induced with 
2 ml of IPTG (1 mM final concentration) and the induced flasks were kept at 37 ˚C for 4 
hours. 
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Sample preparation for purification: 
After 4 hours of induction, the cells were harvested by centrifugation at 5000 rpm for 10 
minutes. The pellets were collected by carefully discarding the supernatant. To each pellet 5 
ml of binding buffer (GE Healthcare His Buffer Kit) was added and the pellets were carefully 
resuspended. To each 5 ml of resuspended solution 0.035 grams of enzyme lysozyme was 
added and mixed thoroughly. Now these solutions tubes were placed on ice for 30 minutes 
and mixed thoroughly for every 5 minutes interval time. After 30 minutes, the samples were 
sonicated and centrifuged at 10,500 rpm for 20 minutes at 4˚ C. The pellet was discarded and 
the supernatant was collected. The collected supernatant was filtered using MILLER-HV 
PVDF 0.45 μm syringe driven filter unit.  
Performing purification for the filtered protein sample: 
The filtered sample was purified by running across the His GraviTrap affinity column (GE 
Healthcare). The steps involved in the purification are: 
1. First, the bottom tip of the column was cut off, then the top cap was removed, excess 
liquid from the column was poured off and the column was placed in the workmate 
column stand. 
2.  Now the column was equilibrated with 10 ml binding buffer to protect the column 
from running dry during the run. Allow the binding buffer to completely run through 
the column.  
3. Now the filtered sample was added to the column. 
4. Once the sample was completely run, 10 ml of binding buffer was added to the 
column and allowed it to completely run out of the column. 
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5. Now 3 ml of elution buffer was added to the column and the eluate was collected in a 
tube. 
Performing dialysis for the eluted protein sample from the column:  
To remove the imidazole from the eluted protein sample, dialysis step was performed using 
dialysis buffer (50 mM sodium phosphate, 100 mM sodium chloride, and 1 mM DTT) at pH-
7.2. The process of dialysis was performed using dialysis cassette (Thermo Scientific Slide-
A-Lyzer Dialysis Cassette of 10,000 MWCO). The cassette was hydrolysed by placing it in 
dialysis buffer for 15 to 20 minutes before loading it with the eluted protein sample. A 
volume of 3 ml eluted protein sample was loaded very gently into the cassette by using 22 
1
/2 
gauge syringe needle. Now the loaded cassette was placed in a beaker containing dialysis 
buffer and magnetic stirrer. The beaker was placed on a magnetic plate. After one hour of 
dialysis, the buffer in the beaker was replaced. This process was continued for overnight and 
the buffer was replaced again on the next day. After one or two hours, the sample was 
collected from the cassette using 22 
1
/2  gauge syringe needle and the concentration of protein 
in the sample was estimated using Bradford protein assay. 
Bradford protein assay:  
The Bradford protein assay is a spectroscopic analytical procedure used to measure the 
concentration of protein in a solution. It was developed by Marion M. Bradford. Here, we 
used the Bio-Rad Protein Assay to measure the concentration of protein. The Bio-Rad Protein 
Assay, based on the method of Bradford, is a simple and accurate procedure for determining 
concentration of solubilized protein. It involves the addition of an acidic dye to protein 
solution, and subsequent measurement at 595 nm with a spectrophotometer or microplate 
reader. Comparison to a standard curve provides a relative measurement of protein 
concentration. The Bio-Rad Protein Assay can also be used with a microplate reader, such as 
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Bio-Rad's Model 450 and 3550 Microplate Readers. Here, we followed the standard 
procedure for microtiter plates and it involves the following steps. 
1. The dye reagent was prepared by diluting one part of dye reagent concentrate with 
four parts of double distilled water. This diluted dye reagent may be used for about 
two weeks when kept at room temperature. 
2. Five dilutions of BSA protein standard were prepared. The linear range of protein 
standard used in this microtiter plate assay is 0.5 mg/ml, 0.4 mg/ml, 0.3mg/ml, 0.2 
mg/ml, and 0.1 mg/ml. To obtain these dilutions, first a 1:20 dilution of BSA (10 
mg/ml) was prepared by adding 10 μl of BSA to 190 μl of double distilled water. 
From this 200 μl, a volume of 40, 30, 20, and 10 μl of BSA were added to a volume 
of 10, 20, 30, and 40 μl of double distilled water respectively to get the above 
mentioned linear range of protein standards.  
3. To prepare unknown protein sample, first a 1:4 dilution of unknown protein sample 
(25 μl of protein sample + 75 μl of double distilled water) was prepared, which was 
further serially diluted in double distilled water by a twofold dilution factor up to 
1:128 dilution.  
4. 10 μl each of standard and unknown protein samples were added into separate 
microtiter plate wells. All standard and unknown protein samples were assayed in 
triplicates. 
5. A volume of 200 μl of diluted dye reagent is added to each well and mixed 
thoroughly. The plate was incubated at room temperature for 3 to 5 minutes and 
absorbance was measured at 595 nm using a microplate reader. 
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6. The concentration of protein in the sample was calculated by comparing its 
absorbance value with the standard curve that is plotted using Microsoft excel by 
plotting protein concentration as the dependent variable on the Y-axis and absorbance 
as the independent variable on the X-axis. 
SDS-PAGE analysis of dialysed protein samples: 
After dialysis, 10 μl of each protein sample from Norwalk virus protease, poliovirus 3C 
protease, and transmissible gastroenteritis virus main protease was mixed with 10 μl of 2X 
LDS buffer respectively and the samples were heated at 95 ˚ C for 3 minutes before loading 
on to the SDS-PAGE gel. A volume of 15 μl of samples was run across a volume of 5 μl EZ-
marker ladder. When the samples were fully run, the gel was washed three times with double 
distilled water for 5 minutes each time and stained with Simply blue for an hour by placing it 
on shaker. After one hour of staining, the gel was destained with double distilled water by 
placing it on shaker. 
FRET enzymatic activity characterization of proteases from Norwalk virus, poliovirus, 
and transmissible gastroenteritis virus  
Substrates: 
Substrate for Norwalk virus protease:  
Two Fluorogenic substrates with edans and dabcyl pair were tested as substrates for Norwalk 
virus protease enzymatic activity. The 14-amino acid fluorogenic substrate edans-
EPDFHLQGPEDLAK-dabcyl and 7-amino acid fluorogenic substrate edans-DFHLQGP-
dabcyl derived from the P7-P7’ and P5-P2’ amino acid residues on the NS2/NS3 cleavage 
site in ORF1 of Norovirus, respectively, were synthesized (GenScript, Piscataway, NJ). The 
representation of substrate residues for P1 and P1’ begins at the scissile bond and counting 
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towards the N-terminus is called P1 side and towards the C-terminus is called P1’ side, 
respectively as suggested by Schechter and Berger [12]. 
Substrate for poliovirus 3C protease: 
The 9-amino acid fluorogenic substrate edans-EALFQGPLQ-dabcyl was synthesized 
(GenScript, Piscataway, NJ) and tested with poliovirus 3C protease and the designation of 
substrate amino acid residues for P1 and P1’ begins at the scissile bond and counting towards 
the N-terminus is called P1 side and towards the C-terminus is called P1’ side, respectively as 
suggested by Schechter and Berger [12]. 
 
Substrate for transmissible gastroenteritis virus 3C-like or main protease: 
The 12-amino acid fluorogenic substrate edans-VNSTLQSGLRKM-dabcyl was synthesized 
(GenScript, Piscataway, NJ) and tested for transmissible gastroenteritis virus main protease. 
FRET protease assay for Norwalk virus protease, poliovirus 3C protease, and 
transmissible gastroenteritis virus main protease to determine the concentration of 
protease that shows maximum enzymatic activity: 
Stock solutions (10 mM) of all the three protease substrates were prepared by dissolving in 
DMSO and these substrates were used for all reactions.   
Optimization of Norwalk virus protease concentration: 
The 25 μl of assay buffer containing different concentrations of Norwalk virus protease (0.5, 
1.0, 3.0, 5.0, and 10 μM,) are mixed with 25 μl of assay buffer containing same concentration 
(20 μM) of 7-amino acid fluorogenic substrate (edans-DFHLQGP-dabcyl) in a 96-well black 
plate and incubated up to 30 min at 37 ˚C. The assay buffer consists of 20 mM HEPES, 120 
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mM NaCl, 0.4 mM EDTA, 4 mM DTT and 20 % Glycerol. The pH of the buffer is adjusted 
to 8.0. The fluorescence signals were detected using an excitation wavelength of 360 nm and 
an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, 
Winooski, VT) every 5 min for 30 min. The fluorescence readings from the substrate control 
well (background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of poliovirus 3C protease concentration: 
The 25 μl of assay buffer containing different concentrations of poliovirus protease (1.0, 5.0, 
10, and 15 μM,) are mixed with 25 μl of assay buffer containing same concentration (20 μM) 
of fluorogenic substrate (edans-EALFQGPLQ-dabcyl) in a 96-well black plate and incubated 
up to 30 min at 37 ˚C. The assay buffer consists of 20 mM HEPES, 120 mM NaCl, 0.4 mM 
EDTA, 4 mM DTT and 20 % Glycerol. The pH of the buffer is adjusted to 6.0. The 
fluorescence signals were detected using an excitation wavelength of 360 nm and an emission 
wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, Winooski, VT) 
every 5 min for 30 min. The fluorescence readings from the substrate control well 
(background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of transmissible gastroenteritis virus main protease concentration: 
 The 25 μl of assay buffer containing different concentrations of transmissible gastroenteritis 
virus main protease (0.1, 0.5, 1.0, and 3.0 μM) are mixed with 25 μl of assay buffer 
containing same concentration (20 μM) of fluorogenic substrate (edans-VNSTLQSGLRKM) 
in a 96-well black plate and incubated up to 30 min at 37 ˚C. The assay buffer consists of 20 
mM HEPES, 120 mM NaCl, 0.4 mM EDTA, 4 mM DTT and 20 % Glycerol. The pH of the 
buffer is adjusted to 6.0. The fluorescence signals were detected using an excitation 
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wavelength of 360 nm and an emission wavelength of 460 nm on a fluorescence microplate 
reader (FLx800, Biotek, Winooski, VT) every 5 min for 30 min. The fluorescence readings 
from the substrate control well (background) were subtracted from the readings of the other 
wells to get the relative fluorescence unit (RFU). 
FRET protease assay for the optimization of assay buffer conditions for proteases from 
Norwalk virus protease, poliovirus 3C protease, and transmissible gastroenteritis virus 
main protease: 
 
Optimization of glycerol percentage: 
Optimization of Glycerol is very important for assay buffer, because it provides stability to 
the enzyme by preventing the rapid loss of enzyme activity. Different percentages of Glycerol 
ranging from 20%, 30%, 40%, and 50% are tested by keeping the remaining all other 
conditions of the buffer (20 mM HEPES, 120 mM NaCl, 0.4 mM EDTA, 4 mM DTT) as 
constant. In case of Norwalk virus protease, pH is adjusted to 8.0, whereas for poliovirus and 
transmissible gastroenteritis virus proteases, pH is adjusted to 6.0. 
Optimization of glycerol percentage for Norwalk virus protease: 
The 25 μl of assay buffer containing 5 μM concentration of Norwalk virus protease is  mixed 
with 25 μl of assay buffer containing 10 μM concentration of 7-amino acid fluorogenic 
substrate (edans-DFHLQGP-dabcyl) in a 96-well black plate and incubated up to 30 min at 
37 ˚C. The fluorescence signals were detected using an excitation wavelength of 360 nm and 
an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, 
Winooski, VT) every 5 min for 30 min. The fluorescence readings from the substrate control 
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well (background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of glycerol percentage for poliovirus 3C protease: 
The 25 μl of assay buffer containing 5 μM concentration of poliovirus protease is mixed with 
25 μl of assay buffer containing 10 μM concentration of fluorogenic substrate (edans-
EALFQGPLQ-dabcyl) in a 96-well black plate and incubated up to 30 min at 37 ˚C. The 
fluorescence signals were detected using an excitation wavelength of 360 nm and an emission 
wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, Winooski, VT) 
every 5 min for 30 min. The fluorescence readings from the substrate control well 
(background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of glycerol percentage for transmissible gastroenteritis virus main 
protease: 
The 25 μl of assay buffer containing 2 μM concentration of transmissible gastroenteritis virus 
main protease is mixed with 25 μl of assay buffer containing 10 μM concentration of 
fluorogenic substrate (edans-VNSTLQSGLRKM) in a 96-well black plate and incubated up 
to 30 min at 37 ˚C. The fluorescence signals were detected using an excitation wavelength of 
360 nm and an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800, 
Biotek, Winooski, VT) every 5 min for 30 min. The fluorescence readings from the substrate 
control well (background) were subtracted from the readings of the other wells to get the 
relative fluorescence unit (RFU). 
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Optimization of dithiothreitol (DTT) concentration: 
Most proteins contain free “SH” groups. Upon oxidation, “SH” turn from intra to inter 
molecular S-S bonds, which usually results in the loss of enzyme activity. A wide variety of 
agents are available to prevent the disulphide bond formation. One among them is DTT, a 
reducing agent which is helpful in maintaining the protein in the reduced state by preventing 
oxidation of cysteines. Different concentrations of DTT (Dithiothreitol) from 0 mM, 2.0 mM, 
4.0 mM, 6.0 mM, 8.0 mM, 10 mM and 30 mM range were tested for Norwalk virus protease , 
transmissible gastroenteritis virus protease and Poliovirus 3C protease. Other than DTT 
concentration, the assay buffer for Norwalk virus consists of 20 mM HEPES, 120 mM NaCl, 
0.4 mM EDTA, and 50 % Glycerol and the pH is 8.0. For poliovirus and transmissible 
gastroenteritis virus proteases, the assay buffer consists of 20 mM HEPES, 120 mM NaCl, 
0.4 mM EDTA, and 20 % Glycerol and the pH is adjusted to 6.0. 
Optimization of DTT concentration for Norwalk virus protease: 
The 25 μl of assay buffer containing 5 μM concentration of Norwalk virus protease is mixed 
with 25 μl of assay buffer containing 10 μM concentration of the 7-amino acid fluorogenic 
substrate (edans-DFHLQGP-dabcyl) in a 96-well black plate and incubated up to 30 min at 
37 ˚C. The fluorescence signals were detected using an excitation wavelength of 360 nm and 
an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, 
Winooski, VT) every 5 min for 30 min. The fluorescence readings from the substrate control 
well (background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
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Optimization of DTT concentration for poliovirus 3C protease: 
The 25 μl of assay buffer containing 5 μM concentration of poliovirus protease is mixed with 
25 μl of assay buffer containing 10 μM concentration of fluorogenic substrate (edans-
EALFQGPLQ-dabcyl) in a 96-well black plate and incubated up to 30 min at 37 ˚C. The 
fluorescence signals were detected using an excitation wavelength of 360 nm and an emission 
wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, Winooski, VT) 
every 5 min for 30 min. The fluorescence readings from the substrate control well 
(background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of DTT concentration for transmissible gastroenteritis virus main 
protease: 
The 25 μl of assay buffer containing 2 μM concentration of transmissible gastroenteritis virus 
main protease is mixed with 25 μl of assay buffer containing 10 μM concentration of 
fluorogenic substrate (edans-VNSTLQSGLRKM) in a 96-well black plate and incubated up 
to 30 min at 37 ˚C. The fluorescence signals were detected using an excitation wavelength of 
360 nm and an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800, 
Biotek, Winooski, VT) every 5 min for 30 min. The fluorescence readings from the substrate 
control well (background) were subtracted from the readings of the other wells to get the 
relative fluorescence unit (RFU). 
Optimization of NaCl concentration: 
Some enzymes require a polar medium with high ionic strength to maintain full activity. Low 
ionic strength favours the rapid inactivation of the enzyme. For these infrequent conditions, 
KCl or NaCl may be used to raise the ionic strength of the solution, thereby providing the 
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stability to the enzyme Different concentrations of NaCl i.e., 0 mM, 50 mM, 100 mM, 200 
mM, and 400 mM were tested for Norwalk virus, poliovirus, and transmissible gastroenteritis 
virus proteases. The remaining buffer conditions for Norwalk virus protease are 20 mM 
HEPES, 0 mM DTT, 0.4 mM EDTA, 50 % glycerol, and pH is adjusted to 8.0. The 
remaining assay buffer conditions for poliovirus and transmissible gastroenteritis virus 
proteases are 20 mM HEPES, 0 mM DTT, 0.4 mM EDTA, 20 % glycerol, and pH is adjusted 
to 6.0. 
Optimization of NaCl concentration for Norwalk virus protease: 
The 25 μl of assay buffer containing 5 μM concentration of Norwalk virus protease is mixed 
with 25 μl of assay buffer containing 10 μM concentration of the 7-amino acid fluorogenic 
substrate (edans-DFHLQGP-dabcyl) in a 96-well black plate and incubated up to 30 min at 
37 ˚C. The fluorescence signals were detected using an excitation wavelength of 360 nm and 
an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, 
Winooski, VT) every 5 min for 30 min. The fluorescence readings from the substrate control 
well (background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of NaCl concentration for poliovirus 3C protease: 
The 25 μl of assay buffer containing 5 μM concentration of poliovirus protease is mixed with 
25 μl of assay buffer containing 10 μM concentration of fluorogenic substrate (edans-
EALFQGPLQ-dabcyl) in a 96-well black plate and incubated up to 30 min at 37 ˚C. The 
fluorescence signals were detected using an excitation wavelength of 360 nm and an emission 
wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, Winooski, VT) 
every 5 min for 30 min. The fluorescence readings from the substrate control well 
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(background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of NaCl concentration for transmissible gastroenteritis virus main 
protease: 
The 25 μl of assay buffer containing 2 μM concentration of transmissible gastroenteritis virus 
main protease is mixed with 25 μl of assay buffer containing 10 μM concentration of 
fluorogenic substrate (edans-VNSTLQSGLRKM) in a 96-well black plate and incubated up 
to 30 min at 37 ˚C. The fluorescence signals were detected using an excitation wavelength of 
360 nm and an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800, 
Biotek, Winooski, VT) every 5 min for 30 min. The fluorescence readings from the substrate 
control well (background) were subtracted from the readings of the other wells to get the 
relative fluorescence unit (RFU). 
Optimization of pH range: 
Biochemical reactions are especially sensitive to pH. Many chemical reactions are affected 
by the acidity of the solution in which they occur. In order for a particular reaction to occur at 
an appropriate rate, the pH of the reaction medium must be controlled. Different levels of pH 
ranging from 6, 7, 8, 9 and 10 were tested for all the three viral proteases. Other than pH and 
glycerol percentage (50 % for Norwalk virus protease, 20 % for poliovirus and transmissible 
gastroenteritis virus proteases), the remaining assay buffer conditions (20 mM HEPES, 0 mM 
DTT, 0.4 mM EDTA, and 0 mM NaCl) are similar for all the three viral proteases. 
Optimization of pH for Norwalk virus protease: 
The 25 μl of assay buffer containing 5 μM concentration of Norwalk virus protease is mixed 
with 25 μl of assay buffer containing 10 μM concentration of the 7-amino acid fluorogenic 
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substrate (edans-DFHLQGP-dabcyl) in a 96-well black plate and incubated up to 30 min at 
37 ˚C. The fluorescence signals were detected using an excitation wavelength of 360 nm and 
an emission wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, 
Winooski, VT) every 5 min for 30 min. The fluorescence readings from the substrate control 
well (background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of pH for poliovirus protease: 
The 25 μl of assay buffer containing 5 μM concentration of poliovirus protease is mixed with 
25 μl of assay buffer containing 10 μM concentration of fluorogenic substrate (edans-
EALFQGPLQ-dabcyl) in a 96-well black plate and incubated up to 30 min at 37 ˚C. The 
fluorescence signals were detected using an excitation wavelength of 360 nm and an emission 
wavelength of 460 nm on a fluorescence microplate reader (FLx800, Biotek, Winooski, VT) 
every 5 min for 30 min. The fluorescence readings from the substrate control well 
(background) were subtracted from the readings of the other wells to get the relative 
fluorescence unit (RFU). 
Optimization of pH for transmissible gastroenteritis virus main protease: 
The 25 μl of assay buffer containing 2 μM concentration of transmissible gastroenteritis virus 
main protease is mixed with 25 μl of assay buffer containing 10 μM concentration of 
fluorogenic substrate (edans-VNSTLQSGLRKM-dabcyl) in a 96-well black plate and 
incubated up to 30 min at 37 ˚C. The fluorescence signals were detected using an excitation 
wavelength of 360 nm and an emission wavelength of 460 nm on a fluorescence microplate 
reader (FLx800, Biotek, Winooski, VT) every 5 min for 30 min. The fluorescence readings 
from the substrate control well (background) were subtracted from the readings of the other 
wells to get the relative fluorescence unit (RFU). 
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FRET protease assay with protease inhibitors for proteases from Norwalk virus 
protease, poliovirus 3C protease, and transmissible gastroenteritis virus main protease: 
To perform FRET protease assay with protease inhibitors, a variety of commercially 
available standard protease inhibitors including serine protease inhibitors such as 
chymostatin, leupeptin, N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), and tosyl-L-
lysine chloromethyl ketone (TLCK) and a papain-like cysteine inhibitor were obtained from 
Sigma-Aldrich (St Louis, MO). Stock solutions of these inhibitors (10 mM) were prepared by 
dissolving in DMSO. Other than pH and glycerol percentage (pH-8, glycerol-50 % for 
Norwalk virus protease; pH-6, glycerol-20 % for poliovirus and transmissible gastroenteritis 
virus proteases), the remaining assay buffer conditions (20 mM HEPES, 0 mM DTT, 0.4 mM 
EDTA, and 0 mM NaCl) are similar for all the three viral proteases.   
Rapid screening of protease inhibitors for Norwalk virus protease: 
For rapid screening of protease inhibitors, 5 μM of Norwalk virus protease and 10 μM of 
substrate that gave strong signal were used. All the five inhibitors (chymostatin, leupeptin, 
TPCK, TLCK, and antipain) at a final concentration of 50 μM and 100 μM were pre-
incubated with 5 μM Norwalk virus protease in 25 μl of assay buffer for 30 minutes at 37˚ C. 
After 30 minutes of pre-incubation, 25 μl of assay buffer containing 10 μM of substrate 
(edans-DFHLQGP-dabcyl) was added to a 96-well black plate and incubated up to 60 
minutes at 37 ˚C. After 60 minutes of incubation, the fluorescence signals were detected 
using an excitation wavelength of 360 nm and an emission wavelength of 460 nm on a 
fluorescence microplate reader (FLx800, Biotek, Winooski, VT).  RFU was calculated by 
subtracting the fluorescent readings of substrate control well (background) from the readings 
of the other wells. The reduction of cleaved products by each preparation was calculated by 
the comparison to that of control well without any inhibitor. 
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Rapid screening of protease inhibitors for poliovirus 3C protease: 
Fast screening of protease inhibitors such as chymostatin, leupeptin, TPCK, TLCK, and 
antipain for poliovirus 3C protease was performed by using 5 μM of protease concentration 
and 10 μM of (edans-EALFQGPLQ-dabcyl) substrate concentration that gave good signal. 
Inhibitors at a concentration of 50 μM and 100 μM are used and the procedure for rapid 
screening of inhibitors is similar to that of Norwalk virus protease. 
Rapid screening of protease inhibitors for transmissible gastroenteritis virus main 
protease:  
A concentration of 2 μM protease and 10 μM substrate concentrations (edans-
VNSTLQSGLRKM-dabcyl) that gave good signal in the studies were used for the quick 
screening of protease inhibitors including chymostatin, leupeptin, TPCK, TLCK, and antipain 
for transmissible gastroenteritis virus main protease. Inhibitors at a concentration of 50 μM 
and 100 μM were tested and the procedure followed is similar to that of rapid screening of 
Norwalk virus protease inhibitors. 
Determination of IC50 of chymostatin and TPCK 
IC50 is the concentration of the inhibitor that inhibited half of the activity of enzyme. The 
IC50 of an inhibitor can be determined by constructing a dose-response curve. 
Determination of IC50 of chymostatin for Norwalk virus protease:  
Among the five inhibitors tested, Norwalk virus protease was strongly inhibited by 
chymostatin at a concentration of 50 μM. So to evaluate the detailed efficacy of chymostatin, 
continuous monitoring of activity of Norwalk virus protease was performed. Protease (5 μM, 
concentration) was mixed with serially diluted chymostatin (0~50 μM) in a 25 μl of assay 
buffer and incubated at 37˚ C for 30 minutes, followed by the addition of 25 μl of assay 
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buffer containing 20 μM substrate (edans-DFHLQGP-dabcyl). The mixture was incubated at 
37˚C for 60 minutes, and fluorescent readings were converted to the concentration of the 
cleavage product as described previously in Materials and Methods, and the dose-dependent 
FRET inhibition curves were fitted with variable slope using WinSAT software in order to 
determine the concentration of chymostatin that reduces enzyme velocity by half (IC50) value. 
Determination of IC50 of TPCK for poliovirus 3C protease:   
Among the five inhibitors tested, poliovirus protease was strongly inhibited by TPCK at a 
concentration of 100 μM compared to 50 μM. So to evaluate the detailed efficacy of TPCK, 
continuous monitoring of activity of Norwalk virus protease was performed. Protease (5 μM, 
concentration) was mixed with serially diluted TPCK (0~150 μM) in a 25 μl of assay buffer 
and incubated at 37˚ C for 30 minutes, followed by the addition of 25 μl of assay buffer 
containing 20 μM substrate (edans- EALFQGPLQ -dabcyl). The mixture was incubated at 
37˚C for 60 minutes, and fluorescent readings were converted to the concentration of the 
cleavage product as described previously in Materials and Methods, and the dose-dependent 
FRET inhibition curves were fitted with variable slope using WinSAT software in order to 
determine the concentration of chymostatin that reduces enzyme velocity by half (IC50) 
value. 
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CHAPTER 4-RESULTS 
The protein expression and SDS-PAGE analysis 
The SDS-PAGE separates the proteins present in each sample fraction into separate bands 
and it can be used to estimate the molecular weight of each protein based on its migration 
distance. The results from the SDS-PAGE analysis for small scale protein expression 
confirmed that the clones that are transferred into BL21 cells are expressing the proteases of 
interest. These results are strongly supported by the results from the SDS-PAGE analysis of 
purified or dialysed samples that showed strong bands with their respective molecular weight. 
The results from the SDS-PAGE analysis showed a predicted molecular weight of 19 kDa for 
Norwalk virus protease, 20 kDa for poliovirus protease, and 33 kDa for transmissible 
gastroenteritis virus (Figure 4.1). 
Estimation of protein concentration in the samples: 
The concentrations of purified protein samples were estimated by using Bio-Rad microtiter 
plate (Bradford) assay. A concentration of 6 mg/ml of Norwalk virus protease was expressed. 
For poliovirus 3C protease, the concentration of protein estimated in the purified sample was 
7 mg/ml, and for transmissible gastroenteritis virus main protease the protein concentration 
was estimated as 3 mg/ml.     
Optimization of protease concentrations: 
All the fluorogenic FRET substrates were efficiently cleaved by their respective proteases. 
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Norwalk virus protease: 
Norwalk virus protease was tested with two substrates, one is 7-amino acids length (edans-
DFHLQGP-dabcyl) and the other is 14-amino acids length (edans-EPDFHLQGPEDLAK-
dabcyl).  Between the two substrates tested for Norwalk virus protease, substrate with 7-
amino acids (edans-DFHLQGP-dabcyl) was more efficiently cleaved and this substrate is 
used for the entire study for Norwalk virus protease. Among the different concentrations of 
protease tested with same concentration of the substrate for Norwalk virus, there is an 
increase in the activity of enzyme with increase in protease concentration (Figure 4.2.A). We 
used a protease concentration of 5μM and a substrate concentration of 10μM for further 
studies of Norwalk virus protease. 
Poliovirus protease: 
The substrate, edans-EALFQGPLQ-dabcyl was used for the enzymatic activity 
characterization of poliovirus 3C protease. Increase in the relative fluorescence confirmed 
that poliovirus 3C protease cleaved the substrate very effectively. Hence, this FRET substrate 
was used for the entire poliovirus enzymatic activity characterization and inhibition studies. 
Poliovirus protease was also tested with different concentrations of protease and same 
concentration of substrate. Relative fluorescence increased with the increase in protease 
concentration. This suggests that poliovirus protease also showed similar kind of activity like 
Norwalk virus protease i.e. increase in the activity of enzyme with the increase in the 
concentration of protease (Figure 4.2.B). We used a protease concentration of 5μM and a 
substrate concentration of 10μM for further studies of poliovirus 3C protease. 
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Transmissible gastroenteritis virus main protease: 
TGEV main protease was tested with the 12-amino acid substrate edans-VNSTLQSGLRKM-
dabcyl for enzymatic activity characterization. A substrate with similar amino acid sequence 
is used for SARS-CoV main protease by Chen. S. et. al (2005). The TGEV main protease 
cleaved the substrate efficiently. Hence, this substrate was used for the enzymatic activity 
characterization and inhibition studies of TGEV main protease. Different concentrations of 
protease were tested with same concentration of substrate. Transmissible gastroenteritis virus 
main protease also showed increase in enzyme activity with the increase in the concentration 
of protease (Figure 4.2.C). We used a protease concentration of 2μM and a substrate 
concentration of 10μM for further studies of transmissible gastroenteritis virus main protease. 
Optimization of assay buffer conditions: 
Assay buffer optimization is very important for the study of enzymatic activity 
characterization, because different enzymes need different buffer conditions. Assay buffer 
conditions were optimized for the each viral protease by testing with different percentages of 
glycerol, different concentrations of NaCl, DTT, and different pH values. 
Glycerol percentage:  
All three viral proteases were tested with different percentages of glycerol ranging from 20% 
to 50% in the assay buffer. 
Norwalk Virus Protease: For the different percentages of glycerol tested, there is an 
increase in the activity of Norwalk virus protease with the increase in glycerol percentage. A 
maximum enzymatic activity was observed at 50 % glycerol for Norwalk virus protease. 
Previously, during preliminary studies, Norwalk virus protease showed maximum activity at 
70% glycerol also. But it became hard to mix the substrate at that percentage of glycerol in 
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the assay buffer. Hence, we selected 50% glycerol in buffer because at this percentage also, it 
showed maximum activity (Figure 4.3.A). 
Poliovirus Protease: Among the different percentages of glycerol tested, Poliovirus 3C 
protease showed maximum activity at 20 and 30 % glycerol in the assay buffer and there is a 
decrease in the activity with the increase of glycerol percentage for poliovirus protease. 
Taking the above results into consideration, we selected 20% of glycerol in the assay buffer 
for further studies of poliovirus protease (Figure 4.3.B). 
Transmissible gastroenteritis virus main protease:  
Transmissible gastroenteritis virus main protease also showed similar kind of activity like 
poliovirus protease at all glycerol percentages tested. TGEV main protease was also tested 
with different percentages of glycerol in the buffer. It showed maximum activity at 20% and 
30% of glycerol in the assay buffer. Further increase in the percentage of glycerol in the 
assay buffer reduced the enzymatic activity of TGEV main protease. Hence, we used 20% of 
glycerol for the further studies of TGEV main protease (Figure 4.3.C). 
DTT concentration:  
Different concentrations of DTT ranging from 0 mM to 30 mM were tested for all the three 
viral proteases.  
Norwalk virus protease:  
Between the ranges of 0 mM to 10 mM the activity of the Norwalk virus protease is almost 
similar and its activity decreased with the increase in the concentration of DTT (30 mM) in 
the assay buffer. In later studies of Norwalk virus protease, we used buffer without DTT in it 
(Figure 4.4.A).  
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Poliovirus Protease: 
Poliovirus protease also showed the same kind of results that are similar to Norwalk virus 
protease. From 0 mM to 10 mM it showed similar kind of activity and it showed reduced 
activity as like Norwalk virus protease with the increase in the concentration of DTT (30 
mM) in the assay buffer. All further studies of poliovirus 3C protease were carried without 
DTT in assay buffer (Figure 4.4.B).  
Transmissible gastroenteritis virus main protease: 
Transmissible gastroenteritis virus showed activity that is different from Norwalk virus 
protease and poliovirus 3C protease. Increase in the concentration of DTT up to 30 mM 
doesn’t show any kind of effect on the activity of TGEV main protease. Transmissible 
gastroenteritis virus main protease showed similar kind of activity (positive activity) from 0 
mM to 30 mM DTT (Figure 4.4.C). Therefore, remaining all studies of TGEV main protease 
was carried without DTT in the assay buffer. 
NaCl concentration:  
Different concentrations of NaCl from 0 mM to 400 mM in assay buffer were tested for each 
protease. 
Norwalk virus protease: 
Norwalk virus protease showed maximum activity without NaCl in buffer, or at low 
concentrations up to 50 mM. There is a decrease in the activity of Norwalk virus protease 
with further increase in the concentration of NaCl (Figure 4.5.A). Hence, assay buffer 
without NaCl was used for Norwalk virus protease. 
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Poliovirus 3C protease:   
Poliovirus 3C protease behaved differently from the other two proteases. It showed almost 
similar activity at all concentrations of NaCl tested. As a result, we selected assay buffer 
without NaCl for poliovirus 3C protease studies (Figure 4.5.B).  
Transmissible gastroenteritis virus main protease:  
Increased concentrations of NaCl showed reduced activity of TGEV main protease. 
Transmissible gastroenteritis virus main protease showed maximum activity without NaCl in 
the assay buffer. Increase in the concentration of NaCl decreased the activity of transmissible 
gastroenteritis virus protease (Figure 4.5.C). Further studies of TGEV main protease was 
also carried without NaCl in the assay buffer like Norwalk virus protease and poliovirus 3C 
protease.  
 pH range:  
All the three viral proteases; Norwalk virus protease, poliovirus 3C protease, and TGEV main 
protease were tested at different pH points from 6.0 to 10.  
Norwalk virus protease: 
At various pH values tested, the Norwalk virus protease exhibited a stable proteolytic activity 
between pH 7.0 – 9.0 and displayed less activity at pH 6.0 and 10. Between pH points 7.0 and 
9.0, Norwalk virus protease showed maximum activity at pH-8.0 (Figure 4.6.A). Hence, 
assay buffer with pH 8.0 was used for Norwalk virus protease studies.  
Poliovirus 3C protease:  
Among various pH points tested, poliovirus 3C protease exhibited maximum proteolytic 
activity between pH 6.0 to 8.0, and displayed very less activity at pH 9.0 and 10. Between pH 
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values 6.0 and 8.0, poliovirus exhibited maximum activity at pH 6.0 (Figure 4.6.B). So, 
assay buffer with pH 6.0 was used for further studies of poliovirus 3C protease.  
Transmissible gastroenteritis virus main protease:  
Among the different pH values tested, transmissible gastroenteritis virus displayed maximum 
proteolytic activity at pH 6.0, and showed medium activity at pH 7.0 and 8.0, but very less 
activity at the pH 9.0 and 10.0 (Figure 4.6.C). Assay buffer with pH 6.0 was selected to use 
for further studies of transmissible gastroenteritis virus main protease. 
Rapid screening of protease inhibitors: 
Five commercially available protease inhibitors including serine protease inhibitors such as 
chymostatin, leupeptin, TPCK, and TLCK and a papain-like cysteine protease inhibitor 
(antipain) were used to identify the inhibitor specificity of each protease. All inhibitors were 
tested at 50 μM and 100 μM concentrations. 
Norwalk virus protease: 
Among all the five protease inhibitors (50 μM and 100 μM) tested, Norwalk virus protease 
was inhibited strongly by chymostatin at both concentrations and a lesser extent by TPCK 
(Figure 4.7.A). As Norwalk virus protease was inhibited by more than 50% at 50 μM 
concentration of chymostatin, IC50 curve was calculated by taking the 50 μM concentration of 
chymostatin as maximum concentration.   
Poliovirus 3C protease: 
Poliovirus 3C protease was inhibited by TPCK and remaining all four protease inhibitors 
were failed to inhibit the protease. Poliovirus 3C protease was strongly inhibited by 100 μM 
concentration of TPCK than 50 μM concentration (Figure 4.7.B). 
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Transmissible gastroenteritis virus main protease:   
Transmissible gastroenteritis virus main protease showed less inhibition profile with all the 
protease inhibitors tested. Interestingly, all these protease inhibitors inhibited the 
transmissible gastroenteritis virus up to a small extent. Among the five inhibitors, it was 
slightly more inhibited by TPCK similar at 50 and 100 μM (Figure 4.7.C). 
Dose response curve analysis: 
Commercially available protease inhibitors including serine protease inhibitors such as 
chymostatin, leupeptin, TPCK, and TLCK and a papain-like cysteine protease inhibitor 
(antipain) were used to identify the inhibitor specificity of each protease.   
 
Norwalk virus protease: 
Norwalk virus protease was strongly inhibited by only chymostatin at both concentrations 
tested for the protease (50 μM and 100 μM) .Chymostatin at 50 μM significantly (more than 
50 %) decreased the fluorescence intensity from inhibition of substrate cleavage by Norwalk 
virus protease. However, antipain, TLCK, TLCK, and leupeptin failed to inhibit Norwalk 
virus protease. Thus, IC50 of chymostatin was determined for Norwalk virus protease. The 
dose response curve for chymostatin on Norwalk virus protease was obtained by using 
WinSTAT software and the IC50 of chymostatin for Norwalk virus protease was determined 
as 37.321 μM chymostatin (Figure 4.8.A). 
Poliovirus 3C protease:  
TPCK at 100 μM significantly inhibited the poliovirus 3C protease. The remaining four 
protease inhibitors chymostatin, TLCK, leupeptin and antipain failed to inhibit poliovirus 3C 
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protease. Thus, IC50 of TPCK (150 μM) was determined for poliovirus 3C protease. The dose 
response curve for TPCK on poliovirus 3C protease were obtained by using WinSTAT 
software and the IC50 of TPCK on poliovirus 3C protease is determined as 68.93 μM of 
TPCK (Figure 4.8.B).  
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CHAPTER 5- DISCUSSION AND CONCLUSIONS 
             Proteases are present in all animal cells and in various subcellular components. An 
enormous variety of biochemical reactions that comprise life are almost mediated by a 
remarkable array of biological catalysts called as enzymes. Proteases also known as 
proteolytic enzymes or proteinases refer to a group of enzymes whose catalytic function is to 
hydrolyze peptide bonds in proteins. They account for about 2% of the human genome, 1-5% 
of genomes of disease causing infectious organisms like bacteria, fungi, viruses, and other 
forms of life (43), (1). Proteolytic enzymes are essential for most physiological process, but 
their overexpression or unregulated actions can lead to many chronically debilitating diseases 
associated with, for example, the CNS and cardiovascular systems, inflammatory and 
neurodegenerative disease conditions, and viral and parasitic infections. 
        Viruses are main pathogenic organisms that can cause a large number of serious diseases 
in humans. For example HIV is responsible for AIDS; herpes simplex virus causes oral 
lesions and genital herpes, hepatitis C virus causes chronic liver diseases cirrhosis and 
hepatocellular carcinoma. There are roughly 170 million chronic HCV carriers in the world, 
or roughly about 3% of the world population (132). As most of the viruses contain RNA as 
their genetic material, the chances of mutation rate is very high and different new strains are 
evolving from the existing strains. Because of their clinical and scientific importance viruses 
have been under intensive study. 
         The discovery and development of new antiviral compounds is an important part of the 
research on viruses. One of the viral components that can be targeted for the development of 
antiviral strategies is viral encoded proteases that are essential for the survival of viruses, as 
well as their infectivity and virulence. These proteases can be targeted for the development of 
antiviral agents because viral proteases play an important role in the processing of viral 
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precursor polyproteins essential to produce functional viral proteins that are required for 
transcription and translation of viral proteins. In the face of such very strong evidence for 
proteases being important mediators of viral pathogenesis, it is not surprising that there has 
been broad research activity and materials targeted to the development of potent and selective 
protease inhibitors, particularly over the last 20 years.  
          In this study, we tried to characterize the enzymatic activity of proteases from Norwalk 
virus, poliovirus, and transmissible gastroenteritis virus by using fast and continuous FRET 
assay and performed the rapid screening of protease inhibitors to figure out potential protease 
inhibitors. These proteases share many common characteristics including a typical 
chymotrypsin-like fold, a Cys residue as a nucleophile in the catalytic triad (or dyad) 
(Figures 5.1, 5.2, and 5.3) composed of Cys, His and Glu (or Asp) residues, and a preference 
for an Glu or Gln residue at the P1 position on the substrate. 
           Noroviruses are recognized as the leading cause of food born-disease outbreaks 
causing acute gastroenteritis around the worldwide, and in the United States (72). They 
spread from person to person, through contaminated food or water, and by touching 
contaminated surfaces. Norovirus infections are mainly confined to schools, hospitals, cruise 
ships, hotels, and military troops and they can affect people of all ages (60). These are 
considered as highly contagious because very few particles less than 100 can initiate infection 
in a healthy individual (21). The symptoms of acute gastroenteritis are diarrhea, vomiting, 
and stomach pain. Long-lasting immunity following natural infection is very rare. The 
genetic variability in circulating noroviruses indicates that individuals are likely to be 
repeatedly infected during their life time (77). Currently there is no vaccine or antiviral 
therapy available for the control of the disease, largely because of the lack of a permissive 
cell culture system for human noroviruses. The National institute of Allergy and Infectious 
Diseases classified noroviruses as category B pathogens because of their highly contagious 
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nature and potential to cause serious public health issue. Considering the above discussed 
challenges, antiviral drugs for controlling norovirus infections are in urgent need.   
         In vitro translation and mutagenesis studies indicated that the 200 kDa polyprotein of 
noroviruses is cleaved by the action of a 3C-like protease to produce three separate functional 
protein products (66). The active amino acid residues in the catalytic site of Norwalk virus 
protease are Cys139, His30, and Glu54. Cys 139 acts as nucleophile (Figure 5.1). The 3C-
like protease of Norwalk virus protease cleaves Gln/Gly or Glu/Gly sequences. In this study 
Norwalk virus 3C-like protease is characterized by using a fluorogenic substrate with 
EDANS-DABCYL pair. For Norwalk virus two fluorogenic substrates one with 14-amino 
acids (edans-EPDFHLQGPEDLAK-dabcyl) substrate derived from P7-P71 and another 
substrate with 7-amino acids (edans-DFHLQGP-dabcyl) substrate derived from P5-P2’ were 
tested. Both the substrates were cleaved by the protease, but the substrate with 7-amino acids 
was more efficiently cleaved indicating that the amino acids at P7, P6, P3’, P4’, P5’, P6’, and 
P7’ in the substrate are not that much important in the process of substrate cleavage by 
Norwalk virus protease. The efficient cleavage of substrate P5-P2’ over P7-P7’ is supported 
by the chromogenic substrate results shown by Hussey et. al. Their experimental results 
showed that chromogenic substrate containing P1- P3 residues was not cleaved by the 
Southampton virus 3C-like protease, and the substrate containing P5- P1 residues was more 
efficiently cleaved compared to that of substrates with P6-P1 or P4-P1 (48). Hence the 
substrate with 7-amino acid residues is used for the enzymatic activity characterization of 
inhibitor studies of Norwalk virus 3C-like protease. 
        The Norwalk virus displayed increase in proteolytic activity with the increasing 
concentrations of protease. This explains the effect of concentration of enzyme during a 
reaction. Assay buffer conditions were optimized for Norwalk virus protease by testing 
different percentages of glycerol, and different concentrations of DTT, NaCl and at various 
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pH values. The optimized assay buffer conditions for Norwalk virus protease is 20 mM 
HEPES, 0 mM NaCl, 0 mM DTT, 0.4 mM EDTA, and 50% glycerol and pH 8.0. 
         Poliovirus is an enterovirus belongs to the family Picornaviridae. Other important 
members of this family that causes important human and animal diseases are hepatitis A virus 
(HAV), coxsackievirus (CV), human rhinovirus (HRV), and foot and mouth disease virus 
(FMDV). Poliovirus is the causative agent of poliomyelitis in humans. Poliovirus was 
identified as causative agent for poliomyelitis in 1908 by Landsteiner and Popper (88). Based 
on slight differences in the capsid protein, poliovirus is divided into three serotypes, PV1, 
PV2, and PV3. All three forms of poliovirus are highly infectious, but among them PV1 is 
the most infectious form in nature (93). This virus is transmitted by fecal-oral route. Most of 
the infections occur in the gastrointestinal tract and the virus is shed in the feces of the 
infected individual. Poliovirus is strictly a human pathogen (99), (84). In most cases of the 
infection only primary viremia is observed and less than 1% of infections only lead to 
paralytic poliomyelitis. Poliovirus polyprotein codes for two viral proteases 2A
pro, 
and 3C
pro
. 
The catalytic site of poliovirus 3C protease consists of Cys147, His40 and Glu71 as active 
amino acid residues. Cysteine147 acts as nucleophile in the process of substrate cleavage 
through proteolysis (Figure 5.2). The 3C protease is the most specific of its class, and cleaves 
solely at Gln↓Gly amino acid pairs. The translated polyprotein is proteolytically cleaved at 9 
of 12 specific processing sites by poliovirus 3C protease and is mainly responsible for the 
production of separate gene products. Poliovirus has two potential vaccines oral polio vaccine 
(OPV) and inactivated polio vaccine (IPV). Even though most of the polio eradication was 
achieved by using OPV and IPV there are some back drops associated with these vaccines 
(22), (130). Hence there is a need to develop antiviral drugs against poliovirus to control the 
outbreaks. The concept of antiviral therapy is not new for poliovirus infection (17). Here, in 
this study a 9-amino acid fluorogenic substrate (edans-EALFQGPLP-dabcyl) was used to 
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characterize the poliovirus 3C protease. The assay buffer conditions were optimized for 
poliovirus 3C protease with the help of fast and continuous FRET protease assay method. 
Generally poliovirus 3C protease cleaves the sessile bond between Gln-Gly pair, preference 
for P4 alanine and P2’ proline residues (82). The substrate was efficiently cleaved by the 
poliovirus 3C protease. The optimized buffer conditions for poliovirus 3C protease were 20 
mM HEPES, 0 mM NaCl, 0 mM DTT, 0.4 mM EDTA, 20% Glycerol, and pH 6.0. 
         Transmissible gastroenteritis virus (TGEV) is coronavirus that causes diarrhea in 
pigs, and piglets under the age of 3 weeks usually die from infection. The other members of 
the genus coronavirus are SARS-CoV, MHV, IBV, and HCoV-229E. Coronaviruses infects 
humans and multiple species of animals. No specific vaccines or drugs are available to 
control HCoV infection. Some vaccines remain several potential problems, even though they 
are developed against IBV, CCoV, and TGEV. 
           PRCV is a variant of TGEV with no enterophathogenic ability and acts like a naturally 
occuring vaccine against TGEV (146). TGEV viral polyprotein processing is mainly achieved 
by main protease or 3C-like protease of 33.1 kDa. The catalytic site (dyad) of transmissible 
gastroenteritis virus main protease consists of Cys144 and His41 as active amino acids 
(Figure 5.3). Cys144 acts as nucleophile during the process of proteolysis. The replicase 
polyproteins are cleaved by the main protease at not less than 11 conserved sites involving 
Leu, Gln ↓ (Ser, Ala, Gly) sequences. To date, no protease inhibitor has been developed for 
TGEV other than existing PRCV attenuated vaccine. TGEV main protease was characterized 
by using 12-amino acid fluorogenic substrate (edans-VNSTLQSGLRKM-dabcyl). The 
substrate was efficiently cleaved by the protease between the P1-P1’ scissile bond and the 
coronavirus main proteases display strong preferences for Gln at P1 position, Leu at P2 
position (2). Similar fluorogenic substrate with 12-amino acids (edans-VNSTLQSGLRK 
(dabcyl)-M was cleaved by SARS-CoV main protease (19) leading to the assumption that the 
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cleavage sites are conserved in coronaviruses. This is supported by work done by Haitao 
et.al. (2005). They synthesized a fluorogenic substrate MCA-AVLQSGFR-Lys (Dnp)-NH2 
based on the assumption that the substrate-binding sites are highly conserved among CoV 
main proteases. The substrate sequence was derived from P4-P5’ of SARS-CoV main 
protease N-terminal auto processing site sequence and it has a sequence AVLQSGFRK.  
Among all the main proteases tested, IBV main protease displayed almost similar Km to that 
of SARS-CoV main protease and four other CoV proteases (TGEV, FIPV, MHV, and HCoV-
229E) showed stronger binding affinity to the substrate than SARS-CoV main protease 
supporting the assumption that substrates of CoV main proteases are conserved (147). The 
optimized assay buffer conditions for transmissible gastroenteritis virus main protease were 
20 mM HEPES, 0 mM NaCl, 0 mM DTT, 0.4 mM EDTA, 20% Glycerol, and pH 6.0. 
        Development of antiviral drugs represents another tool for outbreak control, reduced 
transmission used on their own and work as adjuvants to vaccines. Since viral proteases are 
essential for the processing of the precursor polyprotein to produce mature or functional viral 
proteins, the viral proteases are targeted for the development of antiviral agents. Hence, 
inhibition of the viral protease has the potency to prevent the viral replication; many protease 
inhibitors have shown promising therapeutic activities in preclinical trails in animals and 
early clinical trials in man for viral and parasitic infections (1). A large number of protease 
inhibitors on the market or in the process of development for viruses like HIV, HCV, and 
SARS-CoV are some of the examples (34), (56), and (133).  
          The results from the assay buffer optimization conclude that, even though all the above 
discussed proteases are cysteine proteases which share several common characteristics 
(chymotrypsin-like fold, a Cys residue as nucleophile in the active site); they showed some 
differences in their activity. For example, Norwalk virus 3C protease showed increased 
proteolytic activity with the increase in the percentage of glycerol, whereas poliovirus 3C 
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protease showed maximum activity up to 30 % of glycerol and further increase in glycerol 
percentage decreased the proteolytic activity. TGEV main protease behaved totally different 
that it showed stable proteolytic activity at all glycerol percentages.  
        After optimizing the assay buffer conditions, inhibitor specificities for proteases from 
Norwalk virus, poliovirus, and TGEV were done using commercially available standard 
protease inhibitors. The rapid screening of standard protease inhibitors (chymostatin, 
leupeptin, TPCK, TLCK, and antipain) disclosed that TPCK inhibited NV, PV, and TGEV 
proteases with varying strength, and chymostatin inhibited only NV protease.  
      In summary, in this report, based on FRET assay, four fluorogenic substrates for detection 
of proteolytic activity of their corresponding proteases such as Norwalk virus protease, 
poliovirus 3C protease, and TGEV main protease were evaluated. Among the two substrates 
tested for Norwalk virus protease, the substrate with 7-amino acids showed much more 
efficiency than the substrate with 14-amino acids. Poliovirus 3C protease and transmissible 
gastroenteritis virus cleaved their substrates efficiently under optimized buffer conditions. 
     First, assay conditions of the FRET assay was optimized for each virus protease. Second, 
inhibition profiles of each virus protein were investigated using five commercially available 
standard protease inhibitors (chymostatin, leupeptin, antipain, TPCK, and TLCK). The 
inhibition studies showed that TPCK inhibited NV, poliovirus, and TGEV proteases with 
varying strength, and chymostatin inhibited only NV protease. All other inhibitors had little 
effects on the virus proteases. Finally, the present FRET based assay might supply an ideal 
dais for the large scale screening of inhibitors targeting Norovirus proteases, poliovirus 3C 
protease, and coronaviruses main proteases without time consuming.    
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FIGURES 
Figure 1.1- The process of proteolysis: 
The figure shows the basic structure of a protein’s two amino acids connected by a peptide 
bond represented with dotted line. The protease, by the addition of water cleaves the peptide 
bond and separates the protein into two fragments. The letters R1, R2, and R3 represent side 
chains of each amino acid.  
 
            
 
 
 
 
 
 
 
 
 
 
 
http://pubs.niaaa.nih.gov/publications/arh27-4/317.htm-Intracellular proteolytic systems.  
 
 
 
 
 
 
 
 
Schematic representation of proteolysis 
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Figure 1.2- Cartoon showing common substrate and substrate binding sites for 
proteases: 
The cleavage site (scissile amide bond between P1 and P1’) is indicated by an arrow. Amino 
acid residues towards the left from the cleavage site are called P1, P2, P3, and so on. In the 
similar manner, moving right from the cleavage site are residues P1’, P2’, P3’, and so on. The 
corresponding substrate binding pockets on the protease for these residues are S1, S2, S3, and 
so forth on the left side and S1’ S2’, S3’, and so forth on the right side. 
 
     
 
 
 
 
 
 
 
 
 
 
Abbenante, G., and Fairlie, D. P., (2005). Protease inhibitors in the clinic. Medicinal 
Chemistry, 1, 71-104. 
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Figure 1.3- Serine protease catalytic mechanism: 
The serine protease catalytic mechanism is explained by using chymotrypsin as an example. 
The catalytic site consists of serine 195, histidine 57, and aspartic acid 102. In this 
mechanism, hydrolysis of substrate takes place in two stages. (i) In the first stage, a covalent 
acyl enzyme intermediate is formed by the nucleophilic attack of serine 195 of the enzyme 
(acylation). (ii) Secondly, the covalent acyl enzyme is breakdown by the attack of a water 
molecule releasing the carboxyl end of the peptide (deacylation). These two stages occur in 
the enzyme’s active site with the active participation of histidine 57 and aspartic acid 102. 
 
J Nduwimana et al.(1995). Proteases. Ann Biol Clin (Paris). 53(5):251-64. 
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Figure 1.4- Cysteine protease catalytic mechanism: 
The cysteine protease catalytic mechanism is explained by using papain as an example. The 
catalytic site consists of cysteine 25, and histidine 159. In this mechanism, the hydrolysis of 
the substrate occurs in two stages: acylation and deacylation of the enzyme. (i) In the first 
stage, an acyl enzyme intermediate is formed by the nucleophilic attack of thiol (stabilized by 
imidazolium ion of the adjacent histidine 159) on the carbonyl group of the peptide bond to 
be cleaved. (ii) In the second stage, breakdown of acyl-enzyme intermediate by a water 
molecule releases the carboxyl end of the peptide. 
     
  J Nduwimana et al.(1995). Proteases. Ann Biol Clin (Paris). 53(5):251-64. 
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Figure 1.5- Aspartic acid proteases: 
The aspartic acid protease catalytic mechanism is explained by using pepsin as an example. 
The catalytic site consists of two aspartic acid residues (aspartic acid 32 and aspartic acid 
215) that are linked via a hydrogen bond. In case of aspartic acid proteases, two concurrent 
proton transfers lead to the formation of an impartial tetrahedral intermediate. First, a proton 
from a water molecule transfers to the carboxylate ion of aspartic acid 32, and second proton 
transfer occur from the carboxyl group aspartic acid 215 to the oxygen atom of the carbonyl 
group of the substrate. This tetrahedral intermediate is destroyed by the transfer of proton 
from intermediate to the carboxylate ion of aspartic acid 32, and transfer of another proton 
from carboxyl group of aspartic acid 215 to the nitrogen atom. This leads to the breakdown of 
C-N bond of the substrate. 
         
 
 
J Nduwimana et al.(1995). Proteases. Ann Biol Clin (Paris). 53(5):251-64. 
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Figure 1.6- Metalloproteases catalytic mechanism: 
The active site of metalloproteases consists of a metal ion, usually Zn
2+ 
that is an integral part 
of the protease. Other than metal ion the active site always contains a Glu, sometimes 
associated with Trp or His. The carboxylate ion of the glutamic acid in the active site helps 
the zinc bound to water to make nucleophilic attack on the carbonyl carbon of the substrate to 
form a tetrahedral intermediate. Now carboxylate ion of the glutamic acid transfers the proton 
to the eliminated NH2R’ group which breaks down the tetrahedral intermediate finally 
releasing the carboxylic acid with the help of a water molecule. 
 
 
J Nduwimana et al.(1995). Proteases. Ann Biol Clin (Paris). 53(5):251-64. 
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Figure 2.1- Diagrammatic representation of norovirus genome organization: 
Norovirus genome consists of a molecule of single stranded positive sense RNA of 
approximately 7700 nucleotides with a polyadenylated 3’ terminus. The genome is organized 
into three open reading frames (ORFs): ORF1 located towards the 5’ end encodes a large 200 
kDa non-structural precursor polyprotein, ORF2 and ORF3 located towards the 3’ end 
encodes the major (VP1) and minor (VP2) proteins respectively. 
 
 
 
Figure 2.2- Proteolytic cleavage map of the non-structural proteins of Norwalk virus: 
The 200kDa ORF1 polyprotein is cleaved by the action of 3C-like protease to initially 
generate three separate functional protein products. Full processing of ORF1 precursor 
polyprotein yields six mature non-structural proteins: (i) N-terminal protein (p45), (ii) an 
NTPase (p40), (iii) a 3A-like protein (p22), (iv) a VPg protein (p16), (v) a 3C protease, and 
(vi) an RNA-dependent RNA polymerase (p57). Specifically the protease cleaves at a 
Gln↓Gly or Glu↓Gly pair in the 200 kDa polyprotein (“↓” indicates the cleavage site). The 
protease preferential cleavage sites and the functions of the mature viral proteins are 
indicated in the diagram. 
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Figure 2.3 - Diagrammatic representation of poliovirus genome organization and 
primary cleavage sites of poliovirus polyprotein: 
The genome of poliovirus is approximately 7400 nucleotides in length and composed of a 
single stranded positive sense RNA. It has a VPg at the 5’ end linked to 5’ untranslated 
region (UTR), a single open reading frame that encodes a polyprotein and a 3’ untranslated 
region followed by a poly (A) tail. The polyprotein is divided into three regions, P1, P2, and 
P3 by two virally encoded proteases (2A
pro
 and 3C
pro
). The preferential cleavage site for 3C 
protease is Gln/Gly pair, whereas 2A protease cleaves at a Tyr/Gly pair. 2A protease cleaves 
P1 and P2 (indicated by red arrow) and on the other hand 3C protease cleaves P2 and P3 
(indicated by green arrow). The translated polyprotein is cleaved by 3C protease at 9 of 12 
specific processing sites. 
  
 
       
                       
  
      
 Mature functional proteins.   
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Figure 2.4 – Genomic organization of transmissible gastroenteritis virus: 
The genome of TGEV is a single stranded positive sense RNA of approximately 28, 500 
nucleotides in length and consists of seven open reading frames. ORF1 and ORF2 together 
constitute gene 1, which comprises about two thirds of the genome from the 5’ end. It has a 
leader sequence at the 5’end followed by untranslated region. Another UTR is present at the 
3’end followed by poly (A) tail.ORF1a and ORF1b encode polyprotein 1a and polyprotein 1b 
respectively by ribosomal frame shifting. The processing of these polyproteins produces 
functional proteins that are required for the viral transcription and translation. ORF1 encodes 
two papain like proteases (process the N-terminal region) and a chymotrypsin like protease 
(Main protease) which is responsible for the processing of remaining polyprotein. The 
remaining six ORFs code for structural proteins spike (S), envelope (E), transmembrane (M), 
Nucleocapsid (N).  
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Figure 2.5- Fluorescence resonance energy transfer (FRET) assay: 
In FRET based assays, a substrate is designed on the basis of a sequence that is recognised 
and cleaved by the protease. FRET substrates have a fluorescent donor on one side and a 
fluorescent quencher on the other side of the cleavage site. The donor fluorescence signal is 
quenched by the nearby fluorescent quencher in an uncleaved substrate. In the presence of a 
protease, if the substrate is cleaved, the donor will get separated by the quencher and thereby 
increasing the fluorescence yield of the donor group. Addition of inhibitors will decrease the 
intensity of donor fluorescence signal 
 
 
.
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Figure 4.1- SDS-PAGE analysis of purified proteases: 
The SDS-PAGE analysis results of purified proteases from Norwalk virus, poliovirus, and 
transmissible gastroenteritis virus. The Norwalk virus protease has a predicted molecular 
weight of 19 kDa, poliovirus protease has a predicted molecular weight of 20 kDa, and 
TGEV protease has a predicted molecular weight of 33 kDa. In the figure, lane 1 corresponds 
to molecular weight EZ-marker, lane 2- Norwalk virus protease, lane 3- poliovirus protease, 
and lane 4- TGEV protease. 
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Figure 4.2- Optimization of protease concentrations for Norwalk virus, poliovirus and 
TGEV: 
Different concentrations of proteases are tested with same concentrations of their respective 
substrates. The concentration of substrate used is 20 μM per reaction. A protease 
concentration for each protease is showed on their respective graph. For every protease, 
increase in the concentration of protease increased the enzymatic activity. Here, in this figure, 
(A) corresponds to Norwalk virus protease, (B) corresponds to poliovirus protease, and (C) 
corresponds to TGEV protease. 
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Figure 4.3- Optimization of glycerol percentage in assay buffer: 
The percentage of glycerol is optimized for every protease in this study. A range of glycerol 
percentage from 20 % to 50% was tested for each protease. Norwalk virus protease 
remarkably showed increased enzymatic activity with the increase in the percentage of 
glycerol. Poliovirus showed maximum activity at 20 % and 30%. Further increase in glycerol 
percentage decreased the activity of poliovirus protease. Interestingly TGEV virus showed 
stable activity at all percentages of glycerol tested. In this figure, (A) is Norwalk virus 
protease activity at different glycerol percentages, (B) is poliovirus protease, and (C) is 
TGEV protease activity at different glycerol percentages. 
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Figure 4.4- Optimization of DTT concentration in assay buffer: 
Different concentrations of DTT from 0 mM to 30 mM in the assay buffer are tested for each 
protease. There is no change observed between 0 mM to 10 mM DTT concentration. Norwalk 
virus and poliovirus proteases showed reduced activity at 30 mM concentration of DTT, 
whereas TGEV protease showed stable activity at 30 mM concentration of DTT also. In this 
figure DTT concentration values corresponding to 0 mM and 30 mM are displayed because 
there is no differential change observed between 0 mM and 10 mM concentrations of DTT. In 
this figure, (A) represents Norwalk virus protease, (B) represents poliovirus protease, and (C) 
represents TGEV protease. 
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Figure 4.5- Optimization of NaCl concentration in the assay buffer: 
A different concentration of NaCl (0, 50, 100, 200, and 400 mM) in assay buffer was tested 
for each protease. (A) Norwalk virus showed maximum enzymatic activity at low 
concentrations of NaCl, even better without NaCl in the buffer. (B)Poliovirus demonstrated 
almost similar kind of activity at all concentrations of NaCl tested. (C) TGEV showed 
maximum proteolytic activity without NaCl in the assay buffer and increase in the 
concentration of NaCl decreased the activity of TGEV protease. 
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Figure 4.6- pH range optimization: 
A range of pH values from 6 to 10 are tested for each protease. (A). Norwalk virus protease 
showed maximum enzymatic activity at pH 7 to 9. (B). Poliovirus protease showed maximum 
activity from pH value 6 to 8, but showed more activity at pH 6. (C). TGEV protease 
preferred pH 6 for its maximum enzymatic activity and at pH 7, its activity is reduced by 
50% showing that further increase in pH will decrease the enzymatic activity of TGEV. 
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Figure 4.7- Rapid screening of protease inhibitors: 
All the three proteases were tested against five commercially available protease inhibitors 
namely chymostatin, leupeptin, antipain, TPCK, and TLCK.  The concentrations of inhibitors 
tested were 50 μM and 100 μM respectively for each protease. (A). Norwalk virus was 
maximum inhibited by chymostatin at 50 μM and 100 μM concentrations with very slight 
differences. (B).Among the five inhibitors tested against poliovirus protease, TPCK at 100 
μM concentration inhibited the poliovirus protease more efficiently than 50 μM of TPCK. 
(C). TGEV protease was partially (i.e. less than 50%) inhibited by all the protease inhibitors 
tested and failed to show strong inhibition with any protease inhibitor.  
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Figure 4.8- Dose response curves of chymostatin on Norwalk virus protease and TPCK 
on poliovirus protease: 
(A). Chymostatin at 50 μM concentration is used for getting dose response curve because 
chymostatin at 50 μM concentration showed strong inhibition with Norwalk virus protease. 
Hence, different concentrations of chymostatin (0, 10, 20, 30, 40, and 50 μM) are used to 
calculate IC50 value for chymostatin. (B). similarly for poliovirus protease, TPCK at 150 μM 
concentration is serially diluted to calculate the IC50 value.  
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Figure 5.1A- The crystal 3D structure of Norwalk virus protease: 
The crystal structure of Norwalk virus protease is shown in the figure. The N-(fibre brick) 
and C-terminal (yellow) domains are shown in the figure. Two domains are connected by a 
loop (lime green). β – Strands and helices are represented as arrows and ribbons. The three 
active site amino acid residues [Cys139 (cyan), His30 (blue), and Glu54 (green) are labeled 
and represented in the figure. (PDB ID-2FYQ) 
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Figure 5.1B- Substrate binding sites on the surface of Norwalk virus 3C protease: 
The surface representation of Norwalk virus 3C protease is shown in the figure with 20% 
surface transparency. In the figure, the S1 specificity pocket is shown in orange color; S2 
specificity pocket is shown in purple color and the oxyanion hole is shown in marine color. 
The N-terminal domain is represented by fibre brick color and the C-terminal is represented 
by yellow color. The active amino acids Cys139 is shown in cyan; His30 is shown in blue, 
and Glu54 is shown in green color respectively (PDB ID-2FYQ). 
  
  
 
 
 
Figure 5.1C- The crystal structure of Southampton virus 3C protease linked to an active 
site directed peptide inhibitor: 
The PyMOL molecular graphics 
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The crystal structure of Southampton virus 3C protease is shown in the figure. The N-(fibre 
brick) and C-terminal (yellow) domains are shown in the figure. Two domains are connected 
by a loop (lime green). β – Strands and helices are represented as arrows and ribbons. The 
three active site amino acid residues [Cys139 (cyan), His30 (blue), and Glu54 (green)] are 
labeled and represented in the figure. An active site directed peptide inhibitor (acetyl-Glu-
Phe-Gln-Leu-Gln-X) which is based on the rapidly cleaved recognition sequence in the 200 
kDa polyprotein substrate is also represented as sticks in red color.(PDB ID-2IPH) 
 
 
 
 
 
 
Figure 5.1D- Comparison of Norwalk Virus and Chiba virus 3C proteases: 
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The Norwalk and Chiba virus 3C proteases were aligned using PyMOL molecular graphics. 
The Norwalk virus is shown in cyan color and the Chiba virus is shown in warm pink color. 
Two proteases showed maximum alignment with each other. Active amino acid residues in 
both the proteases were represented sticks with same colours [Cys139 (green), His30 
(orange), and Glu54 (yellow)]. 
   
 
 
 
 
 
 
Figure 5.2A- The crystal 3D structure of poliovirus 3C protease: 
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The 3D diagram of poliovirus 3C protease showing the overall fold is represented here. It 
consists of two domains. Domain I is represented with warm pink and domain II is 
represented with yellow color respectively. β- Strands are indicated by arrows, helices are 
shown as ribbons. Both loop and turn structures are represented as coils. The poliovirus 
active site is comprised of a catalytic triad [Cys147 (green), His40 (cyan), and Glu71 (blue)], 
which is also shown in the diagram. The poliovirus 3C protease active site is similar to, but 
larger than the proteolytic sites of the chymotrypsin-like enzymes. (PDB ID-1L1N) 
 
 
 
 
 
Figure 5.2B- Substrate binding sites on the surface of poliovirus 3C protease: 
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The surface representation of poliovirus 3C protease is shown in the figure with 20% surface 
transparency. In the figure, the S1 specificity pocket is shown in magenta color; S2 
specificity pocket is shown in red color and the oxyanion hole is shown in orange color. The 
active amino acids Cys147 is shown in green; His40 is shown in cyan, and Glu71 is shown in 
blue color respectively (PDB ID-1L1N). 
 
 
 
 
 
 
 
Figure 5.2C- Comparison of Norwalk Virus and poliovirus 3C proteases: 
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The Norwalk and poliovirus 3C proteases were aligned using PyMOL molecular graphics. 
The Norwalk virus is shown in cyan color and the poliovirus is shown in green color. The 
active site cleft of two proteases is conserved between each other, but the cleft of poliovirus 
3C protease is slightly larger than Norwalk virus protease. Active amino acid residues in both 
the proteases were represented as sticks with similar colours. In case of Norwalk virus 3C 
protease Cys139 is shown in orange, His30 is shown in red and Glu54 is shown in magenta. 
Poliovirus Cys147 is represented with orange, His40 is represented with red and Glu71 is 
represented with magenta color.  
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Figure 5.3A- The crystal 3D structure of transmissible gastroenteritis virus main 
protease: 
The 3D structure showing the overall fold of TGEV main protease is shown here. TGEV 
main protease consists of two β – barrel domains and one α – helical C-terminal domain. The 
β – barrels of each domain I (yellow) and II (lime green) are composed of six-stranded β –
sheets. Domain III (tv red) is mainly composed of α- helices. Domains II and III are 
connected by a long blue color loop. α –helices and β –strands are represented as coils and 
arrows, respectively. The active amino acid residues [Cys 144 (red) and His 41 (magenta)] 
are labeled and showed in the figure.  
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Figure 5.3B- Substrate binding sites on the surface of TGEV main protease: 
The surface representation of TGEV main protease is shown in the figure with 40% surface 
transparency. In the figure, the S1 specificity pocket is shown in magenta color; S2 
specificity pocket is shown in orange color and the oxyanion hole is shown in blue color. The 
active amino acids Cys144 is shown in red; His41 is shown in green (PDB ID-2AMP). 
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Table 1.1- Classification of proteases by IUBMB 
Exopeptidases-cleave near the N-or C-termini of peptides and proteins     
IUBMB code Protease name 
EC 3.4.11 Aminopeptidases  
EC 3.4.13 Dipeptides  
EC 3.4.14 Dipeptidyl-peptidases and tripeptidyl peptidases 
EC 3.4.15 Peptidyl-dipeptidases 
EC 3.4.16 Serine-type carboxypeptidases 
EC 3.4.17 metallo carboxypeptidases 
EC 3.4.18 Cysteine-type carboxypeptidases 
 
Endopeptidases-these peptidases cleave internal peptide bonds in proteins and peptides. 
IUBMB code Protease name 
EC 3.4.21 Serine endopeptidases 
EC 3.4.22 Cysteine endopeptidases 
EC 3.4.23 Aspartic endopeptidases 
EC 3.4.24 Metallo endopeptidases 
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Table 1.2- Classification of proteases by MEROPS peptidase database: 
Aspartic acid proteases: 
FAMILY SUBFAMILY EXAMPLE 
A1 A1A Pepsin A(Homo sapiens).  
 A1B Nepenthesin (Nepenthes gracilis).  
A2 A2A HIV-I retropepsin (human immunodeficiency 
virus I). 
 A2B Ty3 transposon peptidase (Saccharomyces 
cerevisiae). 
A3 A3A Cauliflower mosaic virus-type peptidase 
(cauliflower mosaic virus). 
 
Cysteine proteases: 
FAMILY SUBFAMILY EXAMPLE 
C1 C1A Papain (Carica papaya) 
 C1B Bleomycin hydrolase (Saccharomyces 
cerevisiae) 
C2 C2A Calpain-2 (Homo sapiens) 
C3 C3A Poliovirus-type picornain 3C (human 
104 
poliovirus 1) 
 C3B Enterovirus picornain 2A (human poliovirus 
1) 
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